Category: Newsletter Articles & Posts

ICARE Social Media Post June 2023

June 4th: National Cancer Survivor’s Day

Today is National Cancer Survivors Day! Learn how you can support cancer survivors by visiting the American Association for Cancer Research (AACR) website ๐Ÿ‘‡https://www.aacr.org/patients-caregivers/awareness-months/national-cancer-survivor-month/

Permanent link to this article: https://inheritedcancer.net/post60523-2/

ICARE Social Media Post June 2023

VUS Results: Rates of Reclassification in Inherited Cancer Genes

In a multicenter study evaluating reclassifications of variant of uncertain significance (VUS) results in breast, ovarian, and colorectal cancer susceptibility genes, it was discovered that of 3261 VUS results, 8.1% were reclassified. Of all the reclassified VUS results, 11.3% resulted in clinically actionable findings, and 4.6% led to changes in clinical management. The reclassification rates …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60523/

ICARE Social Media Post May 2023

Cancer Care: Transgender and Gender-Diverse Persons

Did you know that transgender and gender-diverse persons face unique challenges that can influence cancer risk and outcomes? For instance, these individuals face barriers to healthcare access and inequities in treatment, with healthcare providers lacking knowledge about the health needs of this population. Solutions are needed to offer the best care for these individuals. Use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52223/

ICARE Social Media Post May 2023

Women’s Health Week

In honor of National Women’s Health Week from May 14th to May 20th, we would like to encourage you to speak with your healthcare provider to make sure you are up-to-date on your cancer screenings, such as mammograms and colonoscopies, to help prevent cancer or find it early when it is easier to treat. Spread …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51523/

ICARE Social Media Post May 2023

ATM breast cancer risks: High Risk c.7271T>G mutation

According to a recent study, while there was a reported 2-fold risk for breast cancer overall among ATM carriers, those with the c.7271T>G mutation had the highest risk. Use the link in our bio to learn more!โ  Reference: Hall et al. Cancer Prev Res (Phila). 2021;14(4):433-440. PMID: 33509806.

Permanent link to this article: https://inheritedcancer.net/post51123/

ICARE Social Media Post May 2023

USPSTF New Recommendation: Mammograms Start at Age 40

Yesterday the United States Preventive Services Task Force (USPSTF) published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years. This change in recommendation is due to recent troubling trends, including an increase in the number of cancers diagnosed …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51023/

ICARE Social Media Post May 2023

Lynch Syndrome: Skin Neoplasms

According to a recent study among individuals with Lynch Syndrome: Use the link in bio to learn more! Reference: Zhong et al. J Am Acad Dermatol. 2023;S0190-9622(23)00173-1. PMID: 36773823.

Permanent link to this article: https://inheritedcancer.net/post50623/

ICARE Social Media Post May 2023

PARP Inhibitors for Metastatic Prostate Cancer: Talazoparib

A study that compared a PARP inhibitor (talazoparib) to the standard of care (an androgen receptor inhibitor) in metastatic castration-resistant prostate cancer found that it improved progression-free survival regardless of BRCA mutation status. However, the benefit was greatest in males with a BRCA or other DNA repair gene mutation. Read the full article at the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50823/

ICARE Social Media Post April 2023

Cancer Risks in Older Females with a BRCA Mutation

A recent study among over 2200 females (aged 50-75) with BRCA mutations, including ICARE participants, found 379 diagnosed cancers with breast and ovarian cancer being the most common cancers observed. Overall cancer risks were 49% in BRCA1 carriers and 43% in BRCA2 carriers, and cancer risks dropped to 9% among those who had preventative removal …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42823/


ICARE Social Media Post April 2023

Prostate Cancer in Black Men: New Genetic Variants to Explain Higher Risks

Researchers identified 9 new genetic variants that may increase the risk of developing prostate cancer. This study highlights the importance of studying diverse populations. Read the full article at the link in our bio!โ  โ Reference:Chen et al. Eur Urol. 2023;S0302-2838(23)02561-7. PMID: 36872133.

Permanent link to this article: https://inheritedcancer.net/post42223/


ICARE Social Media Post April 2023

New study for BRCA1, BRCA2 , or PALB2 carriers with stage 1-3 breast cancer

An open study for BRCA1, BRCA2, or PALB2 carriers with stage 1-3 breast cancer is currently recruiting! Learn more about the study by visiting https://vanderbilt.trialstoday.org/trial/NCT04584255

Permanent link to this article: https://inheritedcancer.net/post42123/


ICARE Social Media Post April 2023

PARP Inhibitors for Metastatic Prostate Cancer: Niraparib

A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link in our bio!โ โ Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.

Permanent link to this article: https://inheritedcancer.net/post42023/

ICARE Social Media Post April 2023

Applying the Framework for Interventions to Increase Family Communication

A new study ๐—ฏ๐˜† ๐—ผ๐˜‚๐—ฟ ๐˜๐—ฒ๐—ฎ๐—บ used the Framework for Developing and Evaluating Complex Interventions (FDECI) to evaluate an intervention to improve family communication of positive genetic test results for inherited cancer. The first FDECI phases were beneficial for improving the intervention and planning for continual effectiveness and future implementation phases. Use the link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41023/

ICARE Newsletter Spring 2023

Community Spotlight

In 1997 when I was a junior in college, my mom called to let me know that my father had been diagnosed with prostate cancer. Luckily for him, Prostate Specific Antigen (PSA) testing had recently started which resulted in early detection and subsequent prostatectomy. Due to his diagnosis and knowing prostate cancer is an inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023span-stylecolor-56b0e4community-spotlight/

ICARE Newsletter Spring 2023

Ask the Expert

The below question was addressed by Ben Ho Park, MD, PhD, who is the Director of the Vanderbilt-Ingram Cancer Center and a Professor of Medicine in the Division of Hematology and Oncology. If you have a question you would like addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: As …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023ask-the-expert/

ICARE Newsletter Spring 2023

Prostate Cancer Treatment Updates

A study to test niraparib (a PARP inhibitor) in males with metastatic prostate cancer showed that those with an inherited BRCA1 or BRCA2 (BRCA) mutation lived longer on average compared to those without a BRCA mutation. Side effects from niraparib were similar to those previously reported with PARP inhibitors.1 Another PARP inhibitor trial tested an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023prostate-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Treatment Updates

Findings from a Phase II study to evaluate the use of talazoparib (a PARP inhibitor) in individuals with advanced PALB2-mutation breast cancer showed that it appeared effective in certain patients and appeared safe (with similar adverse events as those previously reported with this drug).1 There are several Phase II trials to evaluate PARP inhibitors in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Screening in Male BRCA1/2 Carriers

Generally, males with breast cancer present with advanced stage disease, thought to be due to a lack of screening. While data to determine performance of breast screening through mammograms for males at inherited risk is limited, recent studies suggest that the detection rate is similar or better than for females at general population risk.1,2,3 In …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-screening-in-male-brca1-2-carriers/

ICARE Newsletter Spring 2023
Lynch Syndrome: Colorectal Cancer Risks Revisited

While there are higher cancer risks in BRCA mutation carriers starting in the mid-20s, a recent study focused on studying cancer risks in older females aged 50-75. Of the over 2000 females in the study, which included ICARE participants, 379 cancers were found between age 50 to 75 with risks of 49% in BRCA1 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-lynch-syndrome-colorectal-cancer-risks-revisited/

ICARE Newsletter Spring 2023

Lynch Syndrome: Colorectal Cancer Risks Revisited

A study of 381 individuals with Lynch Syndrome in New Zealand (98 with Lynch Syndrome-associated variants in MLH1, 159 in MSH2, 103 in MSH6, and 21 in PMS2) found that risks for colorectal cancer were lower in MSH6 and PMS2 carriers, suggesting that it might be possible to spread out colonoscopy intervals for these individuals.1 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023/

ICARE Newsletter Spring 2023

Inherited Breast Cancer: Contralateral Breast Cancer Risks

While higher risks for contralateral breast cancer (CBC) have been known for BRCA1 and BRCA2, a newly published study demonstrated that the risk of CBC is also higher for female PALB2 and CHEK2 carriers; however, no elevated risks were found for ATM carriers (Table 1).1 This information is important to study, as it may be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-inherited-breast-cancer-contralateral-breast-cancer-risks/

ICARE Newsletter Spring 2023

Melanoma Risk in Li-Fraumeni Syndrome

A recently published cohort study of 483 individuals with Li-Fraumeni Syndrome (LFS) identified 113 skin cancers. The cumulative incidence of a diagnosis of any skin cancer was 36.3% by the age of 70. Specifically for melanoma, the median age at diagnosis was 42 with a 7-fold increased incidence (SIR 7.28, 95% CI 4.50-11.13) compared with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-melanoma-risk-in-li-fraumeni-syndrome/

ICARE Newsletter Spring 2023

National Comprehensive Cancer Network (NCCN) Guidelines Updates

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, PancreaticJanuary 10th, 2023 (Version 2.2023) focused on male BRCA carriers:โ€บ Consider annual mammograms (particularly in BRCA2 carriers) starting at age 50 or 10 years before the earliest male breast cancer in the family (whichever comes first)February 13th, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Social Media Post March 2023

Treatment for PALB2-associated breast cancer with Talazoparib

According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at the link in our bio! Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.

Permanent link to this article: https://inheritedcancer.net/post32723/

ICARE Social Media Post March 2023

New Model: To identify those at high risk for Endometrial (Uterine) Cancer

Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32623/

ICARE Social Media Post March 2023

Inherited Cancer Testing: Pheochromocytoma & Paraganglioma

Because of the high frequency of mutations found in individuals with pheochromocytoma and paraganglioma, these individuals are advised to consider genetic testing for inherited cancer.Use the link in our bio to learn more!โ  Reference: Yip, et al. JAMA Surg. 2022;157 (10):870-877. PMID: 35976622

Permanent link to this article: https://inheritedcancer.net/post32223/

ICARE Social Media Post March 2023

Metachronous Colorectal Cancer in Lynch Syndrome

Findings from a recent study: Risk factors for metachronous colorectal cancer included a history of colorectal polyps and having an MLH1 or MSH2 mutation, while protective factors included female sex and extended surgical resection. This highlights the importance of genetic testing and counseling for Lynch syndrome prior to surgery, which can influence surgical strategy and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31923/

ICARE Social Media Post March 2023

Colorectal Cancer Risks: Lynch Syndrome

A study on colorectal cancer risks in Lynch Syndrome patients found that:โ€ข Colorectal cancer risks were lower in MSH6 and PMS2 carriersโ€ข Colonoscopy intervals for these individuals could be longerโ€ข Incomplete polyp removal may be responsible for 1/3 of surveillance-detected colorectal cancers Read the full article with the link in bio! Reference: Lamba, et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31323/

ICARE Social Media Post March 2023

New gene alert: MBD4

A new study shows germline MBD4 mutations cause an autosomal recessive tumor predisposing syndrome associated with: This highlights the importance of including MBD4 in genetic testing for polyposis and multi-tumor phenotypes to improve disease management. Use the link in bio to learn more! Reference: Palles, et al. Am J Hum Genet. 2022;109(5):953-960. PMID: 35460607.

Permanent link to this article: https://inheritedcancer.net/post31223/

ICARE Social Media Post March 2023

BGREAT December 2022 Newsletter

Check out the latest edition of our B-GREAT newsletter for updates about inherited cancers in the context of racial inequalities in healthcare. You can read the newsletter by visiting ๐Ÿ‘‡https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-December-2022-Newsletter.pdf Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post30623/

ICARE Social Media Post March 2023

Melanoma in TP53 /Li-Fraumeni Syndrome

A new study found a 7-fold increased incidence of melanoma in individuals with TP53/Li-Fraumeni Syndrome compared with the general population:โ€ข Average age was 42โ€ข Risk to age 40 was 2.8%โ€ข Risk to age 60 was 7.8%โ€ข Risk to age 70 was 14.9% Learn more at the link below!https://pubmed.ncbi.nlm.nih.gov/35183552/ Reference: Hatton, et al. J Invest Dermatol. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30723/

ICARE Social Media Post February 2023

Why is learning about inherited cancer important to guide care?

Why have genetic testing? Genetic testing for inherited cancer can help guide care, including:โ€ข Cancer treatment plans, such as chemotherapy, drugs, surgery, and radiationโ€ข Cancer screening and prevention Sharing genetic test results can also help family members understand their cancer risks.โ 

Permanent link to this article: https://inheritedcancer.net/post22423/

ICARE Social Media Post February 2023

ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation

While ATM mutations are generally associated with a 25-30% lifetime risk for breast cancer, emerging information suggests that the risk in those with a c.7570G>C mutation may be higher. Once confirmed, this information may be important to guide cancer screening and risk-reducing surgery decisions. Use the link in our bio to learn more!

Permanent link to this article: https://inheritedcancer.net/post40623/

ICARE Newsletter Spring 2022ย 

ย Community Spotlightย 

Genetic testing sounded like a futuristic concept when it originally came to our attention. It sounded something to the likes of cloning. We didnโ€™t really understand what it was and why it was important, but rather thought it sounded like something out of science fiction. Thankfully, our medical providers and genetic counselors stuck with us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-community-spotlight/

ICARE Newsletter Spring 2022ย 

ย Ask the Expertย 

The below question was addressed by ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid. Dr. Pal is a Professor of Genetic Medicine, Ingram Professor of Cancer Research, and the Associate Director for Cancer Health Disparities at VanderbiltIngram Cancer Center. Dr. Reid is an Assistant Professor of Hematology/Oncology at Vanderbilt University Medical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-ask-the-expert/

ICARE Newsletter Spring 2022ย 

ย Inherited Cancer Treatment Updates

Lynch Syndrome Carriers with Advanced Uterine Cancer: Treatment with PembrolizumabWomen with Lynch Syndrome are at high risk for uterine cancer. The type of uterine cancer they develop has the tumorcharacteristic of being ‘MSI-H’. A new study indicated treatment with pembrolizumab (Keytruda) resulted in benefit inpatients with MSI-H advanced uterine cancer. Von Hippel-Lindau Patients: Treatment of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-inherited-cancer-treatment-updates/

ICARE Newsletter Spring 2022ย 

ย  BRCA1/2 Oral Contraceptives and Breast Cancer

A new study found that among BRCA1/2 carriers, oral contraceptive use strongly lowered cancer risk over oneโ€™s lifetime, even though at first, they raise risks of breast, ovarian, and endometrial cancer.Schrijver et al. J Natl Cancer Inst. 2022 Jan. PMID: 35048954. Social media post February 15th, 2022. Available at:https://tinyurl.com/post21522.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-oral-contraceptives-and-breast-cancer/

ICARE Newsletter Spring 2022ย 

ย  BRCA1/2 and Male Cancer Risksย 

A recent international study found that male BRCA1 and BRCA2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. See the below table for the specific risk levels: Li et al. J Clin Oncol. 2022 Jan. PMID: 35077220. Social media …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-and-male-cancer-risks/

ICARE Newsletter Spring 2022ย 

ย Lynch Syndrome and Prostate Cancer ย 

A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening. Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media postDecember 17th, 2021. Available at: https://tinyurl.com/post121721

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-lynch-syndrome-and-prostate-cancer/

ICARE Newsletter Spring 2022ย 

ย Polygenic Risk Scores and Inherited Breast Cancer Genes: BRCA1/2, PALB2, CHEK2, and ATM ย 

Breast MRIs are advised in women with >20% lifetime risk of breast cancer. A new study showed that breast cancer risks in BRCA1, BRCA2 and PALB2 carriers remained higher than 20%, regardless of whether polygenic risk scores (PRS) were done, suggesting this is of limited help in refining screening. In contrast, PRS downgraded breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-polygenic-risk-scores-and-inherited-breast-cancer-genes-brca1-2-palb2-chek2-and-atm/

ICARE Newsletter Spring 2022ย 

ย Li-Fraumeni Syndrome and Cancer Risksย 

A new study reported on differences in the TP53 mutations between patients who met vs those who did not meet Li-Fraumeni Syndrome (LFS) testing criteria. Several variants were identified multiple times in those who did and did not meet LFS clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282. Other variants were exclusively found in those …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-li-fraumeni-syndrome-and-cancer-risks/

ICARE Newsletter Spring 2022ย 

ย CDH1 and Stomach Cancerย 

A recent study of women with hereditary lobular breast cancer due to CDH1 mutations found high rates ofundetected stomach cancer (with signet ring features). The findings suggested that among CDH1 carriers, there werevery high risks for stomach cancer, even when family history of stomach cancer was absent.Gamble et al. JAMA Surg. 2021 Oct. PMID: 34643667. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-cdh1-and-stomach-cancer/

ICARE Newsletter Fall 2022ย 

ย Community Spotlightย 

When I was just 8 years old my mother was diagnosed with a very aggressive breast cancer. I didnโ€™t reallyunderstand the concept of cancer at that age, but I knew what was happening was terrible. After manysurgeries and treatments, she passed away 2 years later at the age of 35. There was no hereditary cancertesting …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-community-spotlight/

ICARE Newsletter Fall 2022ย 

ย Screening & Treatment Updates: New Modeling Analysis About Breast Cancer Screening in ATM and CHEK2 Carriersย 

Using information from twelve prior population-based studies, a modeling analysis was done to look at when to start mammography and breast MRI in females with inherited mutations in genes including ATM and CHEK2. Overall, findings showed that starting annual MRI screening between age 30 to 35 and mammography at age 40 may lower death from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-new-modeling-analysis-about-breast-cancer-screening-in-atm-and-chek2-carriers/

ICARE Newsletter Fall 2022ย 

ย Screening & Treatment Updates: Pancreatic Cancerย 

A recent small study suggests that immunotherapy may benefit patients with refractory pancreatic or biliary cancer who have inherited a mutation in the homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Another new study reported that in BRCA1/2 carriers with pancreatic cancer, maintenance treatment with Olaparib may be of benefit. Findings showed that with Olaparib, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-pancreatic-cancer/

ICARE Newsletter Fall 2022ย 

ย Which Genes Are Confirmed as ‘Inherited Breast Cancer Genes’?ย 

There were two large studies published early last year that evaluated which genes raise risks for breast cancer, including breast cancer patients from many centers worldwide, representing the largest available datasets to look at this question. These efforts were led by the worldwide Breast Cancer Association Consortium (BCAC)1 and the United States-based CARRIERS consortium. The …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-which-genes-are-confirmed-as-inherited-breast-cancer-genes/

ICARE Newsletter Fall 2022ย 

ย Inherited Cancer Genes: New Associationsย 

A new study led by colleagues at Vanderbilt University Medical Center, including our clinical geneticist colleague, Dr. Georgia Wiesner, evaluated 23 hereditary cancer genes and found 19 new gene associations including 7 new associations with cancer and 12 new associations with noncancer diseases. The associations with cancer versus other conditions is included in the table. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-inherited-cancer-genes-new-associations/

ICARE Newsletter Fall 2022ย 

ย  BRCA1/2 Cancer Risk Updates

During preventive surgery to remove the ovaries and fallopian tubes (called a risk-reducing salpingo-oophorectomy orRRSO), a new study found that the detection of tubal intraepithelial carcinoma predicts the risk of later peritonealcancer.1 These findings show the importance of timely RRSO and the need to do a careful pathology exam of the ovaries and fallopian tubes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-brca1-2-cancer-risk-updates/

ICARE Newsletter Fall 2022ย 

National Comprehensive Cancer Network (NCCN) Guidelines Updatesย 

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic โ€“ Released September 7th, 2022โ€บ Testing eligibility based on personal history of any type of breast cancer in females was updated from age โ‰ค45 to โ‰ค50 making more females with breast cancer eligible for testing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Newsletter Fall 2021ย 

Resource Spotlight: National Cancer Institute’s Cancer Genetics PDQย 

ย 

Looking for a place to get the latest curated information about inherited cancers? Look no furtherโ€ฆ Provide evidence-basedsummaries about inheritedcancer genetics for healthprofessionals and patients Summaries updated basedon monthly review ofpublished literature Written and maintained by amultidisciplinary Editorial Board ofexperts in medical genetics, oncology,and related specialties Visit https://tinyurl.com/NCIPDQ and https://www.cancer.gov/publications/pdq/editorial-boards/genetics for more information

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-resource-spotlight-national-cancer-institutes-cancer-genetics-pdq/

ICARE Newsletter Fall 2021ย 

Direct-to-Consumer Tests: Not Reliable to Detect BRCA1/2 Mutationsย 

Researchers reported that single nucleotide polymorphism (SNP) tests, which are used by DTC tests such as 23andMe, are not reliable in identifying the majority of BRCA1/2 mutations or other inherited cancer gene mutations. The SNP test used by many DTC ancestry and DNA companies is designed to detect common traits many people share. However, when …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-direct-to-consumer-tests-not-reliable-to-detect-brca1-2-mutations/

ICARE Newsletter Fall 2021ย 

Reducing Hereditary Cancer Act of 2021 ย 

Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Thus, genetic testing is only covered for those already diagnosed with cancer, regardless of family history. If someone without cancer has an inherited mutation that increases cancer risk (e.g., BRCA1/2), Medicare may not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6icare-newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-reducing-heredit/

ICARE Newsletter Fall 2021ย 

Community Spotlight

At the age of 51, my first and only colonoscopy revealed 100 polyps in my colon, rectum, and anuseven though I had no symptoms or family history. I was immediately referred to a Certified GeneticCounselor at Tripler Army Medical Center in Hawaiโ€™i. Germline DNA testing revealed I had attenuatedfamilial adenomatous polyposis (AFAP), due to an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-community-spotlight/

ICARE Newsletter Fall 2021ย 

Ask the Expertย 

ย 

In each newsletter, we give participants the opportunity to have their questions addressed by experts in thefield. This question was addressed by Kerry Schaffer, MD, medical oncologist at Vanderbilt University MedicalCenter with a focus on urological cancers. Q. Is there enough information to consider using PARP inhibitors to treat inherited forms ofprostate cancer? A. Over …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-ask-the-expert/

ICARE Newsletter Fall 2021ย 
>

Polygenic Risk Scores and Breast Cancer Risks: BRCA1/2, PALB2, CHEK2, ATM , and beyond!

A recent study found use of a polygenic risk score (PRS) modified the estimated riskof breast cancer among both carriers and non-carriers of inherited breast cancerpredisposition genes. Taking PRS into account, more than 95% of BRCA1, BRCA2,and PALB2 carriers had greater than 20% lifetime risks of breast cancer. In contrast,among ATM and CHEK2 carriers without …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-polygenic-risk-scores-and-breast-cancer-risks-brca1-2-palb2-chek2-atm-and-beyond/

ICARE Social Media Post February 2023

Risk for second breast cancer in premenopausal female BRCA1, BRCA2, PALB2 and CHEK2 carriers

Did you know female BRCA1, BRCA2, CHEK2, or PALB2 carriers have much higher risks for contralateral breast cancer?This information is important to guide cancer screening and risk reduction strategies. Use the link in bio to learn more!

Permanent link to this article: https://inheritedcancer.net/post40123/

Newsletter Fall 2021

Inherited Cancer Treatment Updates

Early-stage, high-risk breast cancer in BRCA carriers: Results of the highly awaited phase 3 OlympiA trial showed promising results for EARLY STAGE (i.e., localized Stage 2-3) high-risk breast cancer patients with a BRCA mutation who were treated with a PARP inhibitor (olaparib) in the adjuvant setting (i.e., AFTER surgery).1 Early-stage breast cancer in this trial …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-inherited-cancer-treatment-updates/

Newsletter Fall 2021

Modifying Risks in BRCA Carriers

Breast cancer risks: A risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) in BRCA carriers was associated with a reduced risk of breast cancer within five years after surgery, with evidence of longer-term risk reduction among those with BRCA1 variants.1 Ovarian cancer risks: A new study reported that the use of oral contraceptives …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-modifying-risks-in-brca-carriers/

Newsletter Fall 2021

Breast Cancer Risks Remain High in PALB2 & BRCA

A new study found that lifetime breast cancer risk is 15% or more in female BRCA1, BRCA2, and PALB2 carriers over age 65. This level of risk warrants consideration for continuing breast MRI.1 These results are similar to those of a study that included ICARE participants,2 which reported the risk of developing breast cancer remains …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-breast-cancer-risks-remain-high-in-palb2-brca/

Newsletter Fall 2021

Prostate Cancer and PALB2

A new Polish study based on two specific founder mutations in PALB2 reported that mutations in this gene may predispose to an aggressive, lethal form of prostate cancer.1 The investigators studied PALB2 prostate cancer risks, characteristics, and outcomes in almost 5,500 men with prostate cancer and compared them to over 8,000 cancer-free adults from Poland. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-prostate-cancer-and-palb2/

Newsletter Fall 2021

PALB2 : Increasingly Recognized as the Third Most Important Inherited Breast Cancer Gene

In May 2021, a clinical practice resource was released by the American College of Medical Genetics and Genomics (ACMG) from a global team of cancer genetics specialists (see figure) to help guide the care of PALB2 carriers.1 PALB2 is considered the third most important breast cancer risk gene, after BRCA1 and BRCA2, with PALB2 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-ipalb2-i-increas/

Newsletter Fall 2021

Updates to NCCN Genetic/Familial High-Risk Assessment

Breast, Ovarian, and Pancreatic Guidelines V.1.2022: Released August 11th, 2021 Colorectal Cancer Guidelines V.1.2021: Released May 11th, 2021 Check out the full NCCN guidelines by creating a FREE account at www.nccn.org

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-updates-to-nccn-genetic-familial-high-risk-assessment/

ICARE Social Media Post January 2023

Inherited Breast Cancers Across Populations

Did you know that BRCA1/2 are amongst the most well-studied genes, yet most BRCA1/2 studies have been done in White populations? This means our knowledge about genes and risks comes primarily from White populations. โ€ข Some research suggests that BRCA1/2 gene mutations may be more common in young Black women with breast cancer. โ€ข Even …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423-2/

ICARE Social Media Post January 2023

Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

The National Comprehensive Cancer Network (NCCN) just released updated breast, ovarian, and pancreatic cancer guidelines which included updated breast cancer screening recommendations for male BRCA carriers (particularly male BRCA2 carriers). It is now recommended that male BRCA carriers consider annual mammograms starting at age 50 or 10 years before the earliest male breast cancer in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423/

ICARE Social Media Post January 2023

New Contralateral Breast Cancer Risk Prediction Model for BRCA1/2 Carriers

A new risk prediction model was developed to assess the risk of contralateral breast cancer in BRCA1/2 carriers. Risks are higher with:โ€ข Younger age at first breast cancerโ€ข Close family member with breast and/or ovarian cancerโ€ข Mutation located near the 3′ region of the gene Risks are lower with:โ€ข Endocrine therapy Use the link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11423/

ICARE Social Media Post January 2023

Why is diversity in genomics studies important?

Did you know that about 80% of genomics data comes from European populations, yet they only make up about 16% of the world population? This bias means Europeans stand to benefit the most, while important associations for other ancestry groups may be missed. Not including diverse populations in genomics research can further WIDEN disparities!

Permanent link to this article: https://inheritedcancer.net/post10823/

ICARE Social Media Post December 2022

Negative or Uninformative Test Results

A new study demonstrates the importance of retesting patients with previously uninformative cancer genetics evaluations, especially in high risk individuals. Read the full article at the link in our bio for more info! ๐Ÿ”—โ  Reference: Dettwyler et al. Fam Cancer. 2022; DOI: 10.1007/s10689-021-00276-8. PMID: 34545504

Permanent link to this article: https://inheritedcancer.net/post121322/

ICARE Social Media Post December 2022

Bilateral Mastectomy in BRCA1/2, PALB2, ATM, & CHEK2 Carriers

A recent study including data from ICARE participants found similar rates of bilateral mastectomy across high (BRCA1, BRCA2, PALB2) and moderate (ATM, CHEK2) penetrance genes. The high rates of bilateral mastectomies seen in those with moderate penetrance genes is concerning for overtreatment. Use the link in our bio to learn more! Reference: Reid et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120822/

ICARE Social Media Post December 2022

Cancer Screen Week

This week is Cancer Screen Week! This week we would like to highlight the importance of screening for inherited cancer to help prevent cancer and find it early. Talk to your healthcare provider today about what screenings are best for you.

Permanent link to this article: https://inheritedcancer.net/post120622/

ICARE Social Media Post November 2022

Cancer Risks: CHEK2

A newly published study reports that the type of CHEK2 mutation leads to different cancer risks. Read the full article at the link in our bio for more info! ๐Ÿ”—โ  Reference: Bychkovsky BL, et al. JAMA Oncol. 2022 Sep 22;e224071. PMID: 36136322.

Permanent link to this article: https://inheritedcancer.net/post112122-2/

ICARE Social Media Post November 2022

Fall 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro-Intestinal Surgical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111122/

ICARE Social Media Post November 2022

Guidelines for Hereditary Breast Cancer Treatment

The Expert Panel Consensus, chaired by the Society of Surgical Oncology with the American Society of Clinical Oncology and the American Society of Radiation Oncology, published new recommendations for hereditary breast cancer treatment. Learn more at https://pubmed.ncbi.nlm.nih.gov/32898012/ Reference: Corso & Magnoni. Eur J Cancer Prev. 2021;30(4):311-314. PMID: 32898012.

Permanent link to this article: https://inheritedcancer.net/post110822/

ICARE Social Media Post November 2022

ICARE Fall 2022 Newsletter

The ICARE Fall 2022 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with Dr. Kamran Idrees from Vanderbilt-Ingram Cancer Center, and an inspiring community spotlight piece. You can read and download a copy of the newsletter at: https://inheritedcancer.net/newsletters/ Please feel free to share with family members, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110422/

ICARE Social Media Post October 2022

Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS)

Have you already had genetic testing for inherited cancer and want to get more education and information about what your results mean for you? We provide free education about inherited cancer risk through our Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS). Visit https://redcap.link/TIPS and complete our survey. Once completed, we provide:โ€ข an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102422/

ICARE Social Media Post October 2022

October 21 – National Mammography Day

National Mammography Day is observed annually on the third Friday of every October. Today acts as reminder to everyone that early detection is the best defense against breast cancer!

Permanent link to this article: https://inheritedcancer.net/post102122/

ICARE Social Media Post October 2022

October 13 Metastatic Breast Cancer Awareness Day

October 13th is Metastatic Breast Cancer Awareness Day. Today is a day to raise awareness about the importance of furthering cancer research.

Permanent link to this article: https://inheritedcancer.net/post101322/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines single post 3

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, genetic testing eligibility based on age at breast cancer diagnosis in females was updated from โ‰ค 45 to โ‰ค 50 making more females with breast cancer eligible for testing regardless of family history …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101022/

ICARE Social Media Post October 2022

CanRisk Tool

Have you heard of the CanRisk Tool?The CanRisk Tool provides health care professionals a user-friendly resource to carry out breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program!Read the full article at the link in bio!Reference: Carver et al. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473. PMID: 33335023.

Permanent link to this article: https://inheritedcancer.net/post100722-2/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, the age to start breast MRI screening in female ATM and CHEK2 carriers was updated from age 40 to 30-35 making more females eligible for screening at an earlier age.Check out the new …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100222/

ICARE Social Media Post October 2022

Ovarian Cancer Risks: Weight Gain in BRCA1/2 Carriers

A study found that adult weight gain is a risk factor for ovarian cancer. This highlights the importance for BRCA1/2 carriers to maintain a healthy weight throughout adulthood.โ Read the full article to learn more! โ https://pubmed.ncbi.nlm.nih.gov/34426412/โ Reference: Kim et al. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043. PMID: 34426412.

Permanent link to this article: https://inheritedcancer.net/post100122/

ICARE Social Media Post September 2022

Breast cancer risks: BRCA1/2 carriers with risk reducing salpingo-oophorectomy (RRSO)

Three recent studies found varying results when evaluating breast cancer risk in BRCA1/2 carriers with risk-reducing salpingo-oophorectomy (RRSO). Use the links in our bio to learn more!

Permanent link to this article: https://inheritedcancer.net/post92722/

ICARE Social Media Post September 2022

Hormonal Replacement Therapy (HRT) in BRCA1 and BRCA2 carriers

A recent study showed hormone replacement therapy (HRT) is reasonable to offer to BRCA1 and BRCA2 carriers who underwent risk-reducing salpingo-oophorectomy (RSSO). Read the full article at the link in our bio for more info! ๐Ÿ”—โ Reference: Mills, et al. Gynecol Oncol; 2020 Jun;157(3):706-710. PMID: 32143914.

Permanent link to this article: https://inheritedcancer.net/post2922/

ICARE Social Media Post September 2022

Bilateral Oophorectomy: Breast Cancer Risks in BRCA1 Carriers

A recent study, including ICARE participants, found preventive removal of the ovaries does not reduce breast cancer risk in BRCA1 carriers. These findings highlight that study bias can influence results.Read the full article at the link in our bio! ๐Ÿ”—โ โ Reference: Kotsopoulos et al. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. PMID: 35477169.

Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-september-2022-bilateral-oophorectomy-breast-cancer-risks-in-brca1-carriers/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 1

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In this new version, a table was added at the end of the guidelines to summarize inherited cancer content across ๐—ฎ๐—น๐—น NCCN guidelines, including live links to the guidelines and sections referenced (see page 54 on the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post92222/

ICARE Social Media Post September 2022
/span>

Risk of Ovarian Cancer In BRCA1/2 Carriers: Oral Contraceptives and Implants

A new study suggests oral contraceptives and implants lower risk of ovarian cancer in BRCA1/2 carriers.Read the full article at the link in our bio for more info! ๐Ÿ”—โ Reference: Xia et al. Gynecol Oncol. 2022;164(3):514-521. doi:10.1016/j.ygyno.2022.01.014. PMID: 35063280.

Permanent link to this article: https://inheritedcancer.net/post92122/

ICARE Social Media Post September 2022

ATM: Breast Cancer Risks

A recent study found that even though ATM has been clearly identified as a breast cancer risk gene with an estimated risk of 13% up to age 80, variant-specific penetrance estimates are needed to guide risk management plans for those with pathogenic mutations.Read the full article at the link in our bio for more info! …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91922/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines.Check out the new guidelines at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91222/

ICARE Social Media Post September 2022

September ICARE Genetics Case Conference

We are excited to announce that our next ICARE genetics case conference, focused on TERT mutations in myeloid malignancies, will be broadly accessible. We are honored to have Mary Armanios, MD as our guest expert for this conference, in which she will provide a featured presentation and case commentary. We encourage you to join us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90822/

ICARE Social Media Post August 2022

Nipple sparing mastectomy: BRCA1/2 carriers

According to a recent study, a bilateral prophylactic nipple-sparing mastectomy appears to be at least equally as safe as other types of mastectomy for preventing breast cancer. Read the full article at the link in our bio for more info! ๐Ÿ”—โ Reference: Stanek et al. Aesthetic Plast Surg. 2022 Apr;46(2):706-711. PMID: 34342702.

Permanent link to this article: https://inheritedcancer.net/post82922/

ICARE Social Media Post August 2022

ATM: Breast Cancer Risks

ATM variants are linked to an increased risk of breast cancer, with the ATM V2424G variant causing the highest risks and ATM D1853V, L546V, and S707P variants being the least predictive.Read the full article here: https://pubmed.ncbi.nlm.nih.gov/33402103/Reference: Moslemi, et al. BMC Cancer. 2021 Jan 5;21(1):27. PMID: 33402103.

Permanent link to this article: https://inheritedcancer.net/post81922/

ICARE Social Media Post August 2022

Ovarian Cancer Risks: Aspirin

A new report found that regular aspirin use was associated with a 13% reduction in ovarian cancer risk. Read the full article at the link in our bio for more info! ๐Ÿ”—โ Reference: Hurwitz et al. J Clin Oncol. 2022. PMID: 35867953.

Permanent link to this article: https://inheritedcancer.net/post81222/

ICARE Social Media Post August 2022

Pancreatic Cancer Treatment

ย 

A new study reports that maintenance treatment with Olaparib may benefit BRCA1/2 carriers with pancreatic cancer. These findings demonstrated:โ long-term survival was more commontime to subsequent therapy was prolongedRead the full article at the link in our bio for more info! ๐Ÿ”—โ โ Reference: Kindler et al. J Clin Oncol. 2022; JCO2101604. PMID: 35834777.

Permanent link to this article: https://inheritedcancer.net/post80522/

ICARE Social Media Post July 2022

Pancreatic Cancer Screening

A recent study found that earlier diagnosis improved survival in people at high risk of pancreatic cancer.High risk was defined based on:family history and/orinherited gene mutation (BRCA1, BRCA2, CDKN2A, Lynch Syndrome genes, PALB2, ATM, and STK11)Read the article at the link in our bio! ๐Ÿ”—โ Reference: Dbouk, et al. J Clin Oncol. 2022 Jun 15:JCO2200298. doi: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72622/

ICARE Social Media Post June 2022

ATM: High and Moderate Risks for Multiple Cancers

A recent study found that pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with multiple cancers. Specifically, moderate-to-high risks for pancreatic, prostate, gastric, and invasive ductal breast cancers, and low-to-moderate risks for ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma.This provides more data to guide risks and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post62122/

ICARE Social Media Post June 2022

Refractory Pancreatic or Biliary Cancer

A recent small study suggests that immunotherapy may be beneficial for patients with refractory pancreatic or biliary cancer who have inherited homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Check out the full article to learn more at ๐Ÿ‘‡https://jamanetwork.com/journals/jamaoncology/article-abstract/2791557Reference: Terrero et al. JAMA Oncol. 2022 Apr:e220611. doi:10.1001/jamaoncol.2022.0611. PMID: 35446342.

Permanent link to this article: https://inheritedcancer.net/post61322/

ICARE Social Media Post June 2022

Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results

A new study found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a small proportion of pregnant women. However, among those with suspicious findings, the risk of a confirmed malignancy was quite high.Check out the full article athttps://ascopubs.org/doi/full/10.1200/JCO.21.02260Reference: Heesterbeek et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60822/

ICARE Social Media Post June 2022

New Variants Linked to Hereditary Cancer

A new study evaluated 23 hereditary cancer genes and found 19 new gene associations, including 7 new associations with cancer and 12 new associations with non-neoplastic diseases. Specifically, the below genes were found to have an increased risk of disease:APC: benign liver/bile duct tumors, gastritis, and duodenitisATM: stomach cancer and pancreatic cancerBRCA1/2: ovarian cystsCHEK2: leukemia …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60122/

ICARE Social Media Post May 2022

BRCA Carriers with Risk-Reducing Salpingo-oophorectomy: Risk of Peritoneal Carcinomatosis

A new study found that among BRCA1/2 carriers, the presence of tubal intraepithelial carcinoma during risk-reducing salpingo-oophorectomy (i.e., preventive surgery to remove the ovaries and fallopian tubes) predicts the risk of later peritoneal cancer. These findings demonstrate:the importance of timely risk-reducing removal of the ovaries and fallopian tubesthat it is VERY important to have a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52422/

ICARE Social Media Post May 2022

Breast Cancer Genes in Women of African Ancestry

A recent study in women of African ancestry confirmed genes previously identified to have associations with breast cancer risk (BRCA1, BRCA2, PALB2, ATM, TP53, NF1, and CHEK2) and provided new evidence of breast cancer risk for RAD51C and RAD51D, which was identified previously in European ancestry populations.Check out the full article at ๐Ÿ‘‡https://pubmed.ncbi.nlm.nih.gov/35396981/Reference: Dรญaz-Zabala, et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51722/

ICARE Social Media Post May 2022

Melanoma Treatment Update

Results from a small study suggest that melanomas in CDKN2A carriers may have better response rates to immunotherapy compared to non-carriers.Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/30291219/Reference: Helgadottir et al. J Med Genet. 2020 May;57(5): 316-321. PMID: 30291219.

Permanent link to this article: https://inheritedcancer.net/post51022/

ICARE Social Media Post May 2022

CDKN2A and Melanoma

Did you know that CDKN2A mutations are found in 35-43% of families with three or more family members with melanoma?Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33945383/Reference: Pissa et al. Acta Oncol. 2021 Jul;60(7):888-896. PMID: 33945383.

Permanent link to this article: https://inheritedcancer.net/post50622/

ICARE Social Media Post April 2022

Spring 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid, discuss the types of inherited breast cancer and whether having an inherited form of breast cancer affects survival.Check …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42922/

ICARE Social Media Post April 2022

Disparities: PARP Inhibitors & Ovarian Cancer

A recent study found that non-Hispanic Black and Hispanic women are underrepresented in clinical trials evaluating PARP inhibitor use among ovarian cancer patients; therefore, these trials do not accurately represent the ovarian cancer patient population. These findings indicate initiatives to increase diversity in clinical trials are needed. Read the full article for more information ๐Ÿ‘‡https://www.gynecologiconcology-online.net/article/S0090-8258(22)00071-3/fulltext#secst0030Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42222/

ICARE Social Media Post April 2022

BRCA1/2 Carriers with Breast Cancer: Olaparib & Survival

A new study found that adjuvant olaparib significantly extended survival in BRCA1/2 carriers with HER2-negative high-risk early-stage breast cancer. Learn more at the following link: https://www.healio.com/news/hematology-oncology/20220323/adjuvant-olaparib-prolongs-survival-for-certain-patients-with-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post41922/

ICARE Social Media Post April 2022

Metastatic Prostate Cancer & Olaparib

Read the full article for more information!https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00017-1/fulltextReference: Thiery-Vuillemin, et al. Lancet Oncol. 2022 Mar;23(3):393-405. PMID: 35157830.

Permanent link to this article: https://inheritedcancer.net/post40822/

ICARE Social Media Post April 2022

Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from Blood Samples

Permanent link to this article: https://inheritedcancer.net/post40522/

ICARE Social Media Post April 2022

Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2

A new study suggests that annual breast MRI screening may reduce deaths from breast cancer by half in women with ATM, CHEK2 and PALB2 gene mutations. The data suggests starting with annual breast MRIs between the ages of 30 to 35, and adding annual mammograms starting at age 40. Read the full article to learn …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post40122/

ICARE Social Media Post March 2022

BRCA1/2: Asian Breast Cancer Patients

A new study highlights the importance of customizing mutation carrier prediction models in order to improve the accuracy of predicting the likelihood of carrying a BRCA mutation in Asian breast cancer patients.Read the article for more info!https://ascopubs.org/doi/abs/10.1200/JCO.21.01647?cid=DM9826&bid=143994923Reference: Hong Ang et al. J Clin Oncol. 2022 Feb 10;JCO2101647. PMID: 35143328.

Permanent link to this article: https://inheritedcancer.net/post32522/

ICARE Social Media Post March 2022

Breast Cancer: Leading Cause Of Cancer-Associated Death Among Black Women

Did you know breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in the United States? Although Black women are at a lower risk for developing breast cancer, they are 41% more likely to die of breast cancer compared with White women.Future research is needed to reverse course, through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31722/

ICARE Social Media Post March 2022

FDA Approves Olaparib for Adjuvant Treatment of High-risk Early Breast Cancer

On March 11th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of BRCA1/2 carriers with human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.Learn more at ๐Ÿ‘‡https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post31522/

ICARE Social Media Post March 2022

Komen Blog Post: Dr. Pal Interview

Komen Scholar, ICARE Founder and Clinical Geneticist, Dr. Tuya Pal, was recently interviewed for the Komen Blog. In the interview, Dr. Pal discusses the importance of making genetic counseling and testing more accessible in order to help populations who are at high risk for inherited cancer make more informed decisions about their medical care.Read the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30922/

ICARE Social Media Post March 2022

Lynch Syndrome: Uterine Cancer Treatment

ย 

A new study indicated treatment with pembrolizumab (Ketruda) resulted in benefit in patients with MSI-H advanced uterine cancer. Read the full article to learn more!https://ascopubs.org/doi/10.1200/JCO.21.01874Reference: O’Malley et al. J Clin Oncol. 2022 Jan 6;JCO2101874. PMID: 34990208.

Permanent link to this article: https://inheritedcancer.net/post30122/

ICARE Social Media Post February 2022

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

A recent study found that only about 33% of women with ovarian cancer undergo germline BRCA1/2 testing, despite universal recommendations for such patients to have germline genetic testing. Check out the article for more information!https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787937?resultClick=3Reference: Cham et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142703. PMID: 35015069.

Permanent link to this article: https://inheritedcancer.net/post22122/

ICARE Social Media Post Month Year

Genetic Testing & Mortality Among Women with Breast or Ovarian Cancer

A recent study found there were BETTER short-term outcomes among women with:โ€ข triple-negative breast cancer and BRCA1 or BRCA2 mutationsโ€ข ovarian cancer and BRCA2, BRIP1, RAD51C, or ATM mutationsThese findings may be reassuring to individuals with inherited gene mutations related to breast and ovarian cancer. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/34373918/Reference: Kurian et al. J …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21822/

ICARE Social Media Post February 2022

BRCA1/2 Cancer Risks: Oral Contraceptives

A new study found that among BRCA1/2 carriers oral contraceptive use strongly decreases lifetime cancer risk, despite an ๐—ถ๐—ป๐—ถ๐˜๐—ถ๐—ฎ๐—น increase in breast, ovarian, and endometrial cancer risk. Read the full article to learn more!https://pubmed.ncbi.nlm.nih.gov/35048954/Reference: Schrijver et al. J Natl Cancer Inst. 2022 Jan 20;djac004. PMID: 35048954

Permanent link to this article: https://inheritedcancer.net/post21522/

ICARE Social Media Post February 2022

Polygenic Risk Scores: BRCA1, BRCA2, PALB2, CHEK2 & ATM

Permanent link to this article: https://inheritedcancer.net/post20822/

ICARE Social Media Post February 2022

Breast Cancer Characteristics Across Genes

ย 

A new study demonstrated that breast cancer pathology and other clinical features differ by inherited breast cancer gene. Read the full article to learn more!https://jamanetwork.com/journals/jamaoncology/fullarticle/2788577Reference: Breast Cancer Association Consortium. JAMA Oncol. 2022 Jan 27. PMID: 35084436

Permanent link to this article: https://inheritedcancer.net/post20122/

ICARE Social Media Post January 2022

Male Cancer Risks: BRCA1 & BRCA2

A new study found that male BRCA1/2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. Read the full Journal of Clinical Oncology article to learn more!https://ascopubs.org/doi/full/10.1200/JCO.21.02112Reference: Li et al. J Clin Oncol. 2022 Jan 25;JCO2102112. PMID: 35077220.

Permanent link to this article: https://inheritedcancer.net/post12822/

ICARE Social Media Post January 2022

Overview of genetic services delivery for hereditary breast cancer

A recent article by Drs. Sonya Reid, Tuya Pal, and Lucy Spalluto, and Katie Lang, MS, CGC and Anne Weidner, MPH of the ICARE team, has just been published with @SpringerNature in ๐˜‰๐˜ณ๐˜ฆ๐˜ข๐˜ด๐˜ต ๐˜Š๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ ๐˜™๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ ๐˜ข๐˜ฏ๐˜ฅ ๐˜›๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต. This article outlines the importance of genetic services and follow-up care for hereditary breast cancer, as well as …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12622/

ICARE Social Media Post January 2022

BRCA Breast Cancer Risks After Age 60

A study that included ICARE participants reported the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 carriers. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33423179/Reference: Stjepanovic et al. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. PMID: 33423179

Permanent link to this article: https://inheritedcancer.net/post12522/

ICARE Social Media Post January 2022

Belzutifan in Von Hippel-Lindau Disease Patients

Belzutifan demonstrated clinical efficacy in patients with renal cell carcinoma who have Von Hippel-Lindau Disease. Learn more by reading the full The New England Journal of Medicine article at ๐Ÿ‘‡https://www.nejm.org/doi/full/10.1056/NEJMoa2103425Reference: Jonasch, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. PMID: 34818478.

Permanent link to this article: https://inheritedcancer.net/post12122/

ICARE Social Media Post January 2022

Dr. Pal’s GIM Editorial

ย 

Estimating Polygenetic Risk Scores in non-Europeans through extrapolating from data in European descent populations is not accurate! Diversity in genomic studies is critically needed for both equity and scientific discovery. For more information, read the Genetics in Medicine editorial by ICARE Founder, Dr. Tuya Pal, here ๐Ÿ‘‡https://www.gimjournal.org/article/S1098-3600(21)05396-X/fulltextReference: Pal. Genet Med. 2021 Nov 20;S1098-3600(21)05396-X. PMID: 34906472.

Permanent link to this article: https://inheritedcancer.net/post11822/

ICARE Social Media Post January 2022

Gastric Cancer Risks: CDH1

Read the ๐˜‘๐˜ˆ๐˜”๐˜ˆ ๐˜š๐˜ถ๐˜ณ๐˜จ๐˜ฆ๐˜ณ๐˜บ article to learn morehttps://jamanetwork.com/journals/jamasurgery/article-abstract/2785097Reference: Gamble et al. JAMA Surg. 2021 Oct 13;e215118. PMID: 34643667.

Permanent link to this article: https://inheritedcancer.net/post11122/

ICARE Social Media Post January 2022

Ovarian Cancer: BRCA1/2 Maintenance Olaparib

Read the full article for more details ๐Ÿ‘‡https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextReference: Banerjee et al. Lancet Oncol. 2021 Dec;22(12):1721-1731. PMID: 34715071.

Permanent link to this article: https://inheritedcancer.net/post10422/

ICARE Social Media Post December 2021

Fall 2021 Community Spotlight

In every ICARE newsletter we feature a ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐˜† ๐˜€๐—ฝ๐—ผ๐˜๐—น๐—ถ๐—ด๐—ต๐˜ to share their experience with inherited cancer. In the latest edition, Dan Dry Dock Shockley, shares his experience with attenuated familial adenomatous polyposis (AFAP). Check out his full story at ๐Ÿ‘‡https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post123021/

ICARE Social Media Post December 2021

Fall 2021 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kerry Schaffer discusses the use of PARP inhibitors to treat inherited forms of prostate cancer.Check out Dr. Schaffer’s full response at ๐Ÿ‘‡https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/post122821/

ICARE Social Media Post December 2021

Breast Cancer Risk Prediction Model for Black Women

ย 

A new breast cancer model has been developed and validated for breast cancer risk prediction, specifically for Black women in the United States. This is in contrast to prior models, which were developed in White women, and used in Black women (which UNDERPREDICTED risks). This is a notable advance as we strive towards health equity …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122321/

ICARE Social Media Post December 2021

Li-Fraumeni Syndrome Cancer Risks

โ€ข Several variants were identified multiple times in those who did and did not meet Li-Fraumeni Syndrome clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282โ€ข Other variants were exclusively found in those in the Li-Fraumeni Syndrome group: p.M133T, p.P152L, p.C275Y, p.C275, p.R337C, p.R342, and p.R342Pโ€ข One variant was exclusively found in patients with attenuated Li-Fraumeni …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122121/

ICARE Social Media Post December 2021

Prostate Cancer Screening: MSH2 & MSH6

A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more ๐Ÿ‘‡ https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.

Permanent link to this article: https://inheritedcancer.net/post121721/

ICARE Social Media Post December 2021

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at ๐Ÿ‘‡https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769

Permanent link to this article: https://inheritedcancer.net/post121021/

ICARE Social Media Post December 2021

FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer

FDA granted priority review to Olaparib for adjuvant treatment of certain patients with high-risk breast cancer. This designation applies to use of the agent by patients with BRCA-mutated, HER2-negative, high-risk early breast cancer who receive chemotherapy before or after surgery. For additional information, visit: https://tinyurl.com/healioFDAapproval

Permanent link to this article: https://inheritedcancer.net/post120621/

ICARE Social Media Post December 2021

The Impact of Subtype and Race on Breast Cancer Survival

A recent article ๐—น๐—ฒ๐—ฑ ๐—ฏ๐˜† ๐——๐—ฟ๐˜€. ๐—ฆ๐—ผ๐—ป๐˜†๐—ฎ ๐—ฅ๐—ฒ๐—ถ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐—ง๐˜‚๐˜†๐—ฎ ๐—ฃ๐—ฎ๐—น ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—œ๐—–๐—”๐—ฅ๐—˜ ๐˜๐—ฒ๐—ฎ๐—บ, published in ๐˜‰๐˜ณ๐˜ฆ๐˜ข๐˜ด๐˜ต ๐˜Š๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ ๐˜™๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ ๐˜ข๐˜ฏ๐˜ฅ ๐˜›๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต, outlines the impact of race and molecular subtype on HR+, HER2- breast cancer survival. Check out the full article at https://link.springer.com/content/pdf/10.1007/s10549-021-06342-0.pdf Reference: Reid et al. Breast Cancer Res Treat. 2021 Oct;189(3):845-852. PMID: 34331630.

Permanent link to this article: https://inheritedcancer.net/post120321/

ICARE Social Media Post November 2021

Variation in Colorectal Cancer Risk in Families With Lynch Syndrome

For more information, read the Lancet Oncology article led by The International Mismatch Repair Consortium at the below link ๐Ÿ‘‡https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00189-3/fulltext Reference: International Mismatch Repair Consortium. Lancet Oncol. 2021 Jul;22(7):1014-1022. PMID: 34111421.

Permanent link to this article: https://inheritedcancer.net/post113021/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, view the article at ๐Ÿ‘‡https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab141/6323231 Reference: Johnson et al. PMID: 34291289.

Permanent link to this article: https://inheritedcancer.net/post110921/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, read the full article at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782345

Permanent link to this article: https://inheritedcancer.net/post110221/

ICARE Social Media Post October 2021

Pancreatic Cancer Risks: ATM

For more information, read the full article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2783767 Reference: Hsu, et al. JAMA Oncol. 2021 Sep 16:e213701. PMID: 34529012.

Permanent link to this article: https://inheritedcancer.net/post100121/

ICARE Social Media Post September 2021

USA Today Article: Fighting Cancer with Your Own Family History

Check out the full ๐˜œ๐˜š๐˜ˆ ๐˜›๐˜ฐ๐˜ฅ๐˜ข๐˜บ article, featuring commentary from Dr. Tuya Pal (ICARE Founder), highlighting the importance of PALB2 as an inherited breast cancer gene: https://www.futureofpersonalhealth.com/breast-health/fighting-cancer-with-your-own-family-history/# Additional guidance is available through an impactful PALB2 practice resource recently published through ACMG: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Reference: Tischkowitz, et al. Genet Med. 2021 Aug;23(8):1416-1423. PMID: 33976419

Permanent link to this article: https://inheritedcancer.net/post92221/

ICARE Social Media Post September 2021

New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines (Released August 11th)

The National Comprehensive Cancer Network (NCCN) released new guidelines on August 11th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91021/

ICARE Social Media Post August 2021

Genetic Risk Assessment for Hereditary Renal Cell Carcinoma

To view the 30 consensus statements, read the full article at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33679

Permanent link to this article: https://inheritedcancer.net/post83121/

ICARE Social Media Post August 2021

Breast Cancer Risks: BRCA1/2 & PALB2

For more information, view the article at ๐Ÿ‘‡https://ascopubs.org/doi/full/10.1200/JCO.21.00531

Permanent link to this article: https://inheritedcancer.net/post82421/

ICARE Social Media Post August 2021

Metastatic Breast Cancer Genes

For additional information, read the Journal of Clinical Oncology article at the link below ๐Ÿ‘‡ https://ascopubs.org/doi/10.1200/JCO.20.01200

Permanent link to this article: https://inheritedcancer.net/post82021/

ICARE Social Media Post August 2021

New York Times PALB2 Article

A New York Times article just published focused on the importance of PALB2 as a breast cancer gene (https://www.nytimes.com/โ€ฆ/breast-cancer-palb2-brca.html), which referenced our recent article focused on managing PALB2 carriers sponsored by ACMG – American College of Medical Genetics and Genomics, and developed through a worldwide collaboration (including: Marc Tischkowicz, Judith Balmana, Will Foulkes, Paul James, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81921/

ICARE Social Media Post August 2021

Germline Testing & Advanced Cancers

Check out the article for more information: https://ascopubs.org/doi/pdf/10.1200/JCO.20.03661

Permanent link to this article: https://inheritedcancer.net/post81621/

ICARE Social Media Post August 2021

Breast Cancer Risk Among Breast Cancer Gene Carriers Varies by Polygenic Risk Score

For more information, read the ๐˜‘๐˜ฐ๐˜ถ๐˜ณ๐˜ฏ๐˜ข๐˜ญ ๐˜ฐ๐˜ง ๐˜Š๐˜ญ๐˜ช๐˜ฏ๐˜ช๐˜ค๐˜ข๐˜ญ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ article at the link below:https://ascopubs.org/doi/figure/10.1200/JCO.20.01992

Permanent link to this article: https://inheritedcancer.net/post81321/

ICARE Social Media Post August 2021

ASCO Guideline Update: Olaparib for Breast Cancer

For additional information, read the updated American Society of Clinical Oncology (ASCO) recommendation (released June 15th, 2021) at the following link: https://www.asco.org/practice-patients/guidelines/breast-cancer?intcmp=ws_ascoorg_gdlns_hereditarybreastcancer_site_pressrelease_061621____#/143725

Permanent link to this article: https://inheritedcancer.net/post81021/

ICARE Social Media Post August 2021

Oral Contraceptive Use & Reduced Ovarian Cancer Risk in BRCA Carriers

For more information, view the AJOG article by Lieske Schrijver and colleagues at the following link: https://www.ajog.org/article/S0002-9378(21)00038-7/fulltext

Permanent link to this article: https://inheritedcancer.net/post80621/

ICARE Social Media Post August 2021

BRCA Mutations in Indian Women with Ovarian Cancer

For more information, view the article at: https://ascopubs.org/doi/full/10.1200/GO.21.00051

Permanent link to this article: https://inheritedcancer.net/post80321/

ICARE Social Media Post July 2021

Inherited Cancer in Colorectal Cancer Patients

For more information, view the article at: https://ascopubs.org/doi/10.1200/PO.20.00525

Permanent link to this article: https://inheritedcancer.net/post72721/

ICARE Social Media Post July 2021

Lifestyle & Colorectal Cancer Risk

For additional information, read the article at the link below: https://academic.oup.com/ajcn/article-abstract/113/4/810/6155851

Permanent link to this article: https://inheritedcancer.net/post72021/

ICARE Social Media Post July 2021

Niraparib Maintenance in BRCA Carriers with Ovarian Cancer

For more information visit: https://www.cancernetwork.com/view/multi-trial-analysis-indicates-niraparib-maintenance-for-brca-ovarian-cancer-leads-to-pfs-benefit-across-settings

Permanent link to this article: https://inheritedcancer.net/post71621/

ICARE Social Media Post July 2021

Disparities in Cancer Survival Among Adolescents and Young Adults

Check out the full article for more information: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab006/6117446

Permanent link to this article: https://inheritedcancer.net/post71321/

ICARE Social Media Post July 2021

RAD51C & RAD51D Response to Rucaparib in Ovarian Cancer

Check out the Nature Communications article for more information: https://www.nature.com/articles/s41467-021-22582-6

Permanent link to this article: https://inheritedcancer.net/post70921/

ICARE Social Media Post July 2021

Advances in Pancreatic Cancer Treatment: PALB2 & BRCA1/2

For more information, view the article at the following link below: https://ascopubs.org/doi/abs/10.1200/JCO.21.00003 You may also read the ASCO post article at: https://ascopost.com/news/may-2021/maintenance-rucaparib-in-patients-with-platinum-sensitive-pancreatic-cancer-and-germline-or-somatic-brca1-brca2-or-palb2-variants/?utm_source=TAP%2DEN%2D051221%2DTrending%5FLymphoma&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769

Permanent link to this article: https://inheritedcancer.net/post70621/

ICARE Social Media Post July 2021

PALB2 & Prostate Cancer

For more information, read the article available at: https://www.nature.com/articles/s41416-021-01410-0

Permanent link to this article: https://inheritedcancer.net/post70221/

ICARE Social Media Post June 2021

BRCA: Better Survival with Screening

For more information, please visit: https://www.cancertherapyadvisor.com/home/news/conference-coverage/st-gallen-international-breast-cancer-conference/sg-bcc-2021/breast-cancer-screening-brca-improves-survival-mutation

Permanent link to this article: https://inheritedcancer.net/post62921/

ICARE Social Media Post June 2021

A Population-Based Study of Genes Previously Implicated in Breast Cancer

For additional information, read the article at the following link: https://www.nejm.org/doi/10.1056/NEJMoa2005936

Permanent link to this article: https://inheritedcancer.net/post62521/

ICARE Social Media Post June 2021

BRCA2 Variants of Uncertain Significance

For more information, view the article at: https://pubmed.ncbi.nlm.nih.gov/33609447/

Permanent link to this article: https://inheritedcancer.net/post62221/

ICARE Social Media Post June 2021

Actionable Pathogenic Variants Among Caribbean-Born People With Breast or Ovarian Cancer

For more information, view the article at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776805

Permanent link to this article: https://inheritedcancer.net/post61521/

ICARE Social Media Post June 2021

Olaparib In Patients With Early, High-Risk HER2-Negative Breast Cancer & BRCA Mutations

For more information view the article at: https://www.nejm.org/doi/full/10.1056/NEJMoa2105215

Permanent link to this article: https://inheritedcancer.net/post61121/

ICARE Social Media Post May 2021

Race-Based Oncology

For more information, view the article at the following link: https://ascopubs.org/doi/full/10.1200/PO.20.00418

Permanent link to this article: https://inheritedcancer.net/post52821/

ICARE Social Media Post May 2021

Breast Cancer Awareness Medical Minute

In recognition of ๐—ช๐—ผ๐—บ๐—ฒ๐—ป’๐˜€ ๐—›๐—ฒ๐—ฎ๐—น๐˜๐—ต ๐— ๐—ผ๐—ป๐˜๐—ต, listen to our colleague, Dr. Sonya Reid, talk about the importance of mammography for the early detection of breast cancer! To learn more, check out the American Cancer Society’s Recommendations for the Early Detection of Breast Cancer at: https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

Permanent link to this article: https://inheritedcancer.net/post52421/

ICARE Social Media Post May 2021

USPSTF Earlier Colorectal Cancer Screening At Age 45

The United States Preventive Services Task Force (USPSTF) now recommends routine colorectal cancer screening begin at age 45 (lowered from the previous recommendation to start screening at age 50) due to an increasing number of colorectal cancer cases in younger adults. For more information, check out the full JAMA article at: https://jamanetwork.com/journals/jama/fullarticle/2779985

Permanent link to this article: https://inheritedcancer.net/post52121/

ICARE Social Media Post May 2021

ACMG Gene List

The American College of Medical Genetics and Genomics (ACMG) recently released the highly anticipated recommended minimum gene list for reporting secondary findings (SF) in clinical exome and genome sequencing. ACMG SF v3.0 added 3 new cancer genes (๐˜—๐˜ˆ๐˜“๐˜‰2, ๐˜”๐˜ˆ๐˜Ÿ, and ๐˜›๐˜”๐˜Œ๐˜”127) to bring the total number of inherited cancer genes to 28. For more information …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52121_2/

ICARE Social Media Post May 2021

Plexiform Neurofibromas and NF1

For more information, read the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.02220

Permanent link to this article: https://inheritedcancer.net/post51821/

ICARE Social Media Post May 2021

CDKN2A: Cancer Risks and Risk Management

๐˜๐˜ฏ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜จ๐˜ฏ๐˜ช๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ฐ๐˜ง ๐˜ด๐˜ฌ๐˜ช๐˜ฏ ๐˜ค๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ ๐˜ข๐˜ธ๐˜ข๐˜ณ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜ฎ๐˜ฐ๐˜ฏ๐˜ต๐˜ฉ, we present cancer risks and management for ๐—–๐——๐—ž๐—ก๐Ÿฎ๐—” per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Version 2.2021 ๐— ๐—ฒ๐—ป & ๐—ช๐—ผ๐—บ๐—ฒ๐—ป:Melanoma risk: Elevated at 28-67% – Recommend annual full-body skin exam, regular self-examinations, and routine sun protective behaviors. Pancreatic cancer risk: >15% – Consider MRI/MRCP and/or endoscopic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51321/

ICARE Social Media Post May 2021

ACMG Clinical Practice Resource on PALB2

Check out the newly released ACMG Clinical Practice Resource on ๐—ฃ๐—”๐—Ÿ๐—•๐Ÿฎ developed through a group of worldwide experts!https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Read the ACMG press release at: https://www.acmg.net/PDFLibrary/Global%20Team%20of%20Cancer%20Genetic%20Specialists%20release%20final%20template%205%206.final.pdf

Permanent link to this article: https://inheritedcancer.net/post51121/

ICARE Social Media Post May 2021

Direct-to-Consumer Tests

For additional information, view the BMJ article available at: ๐Ÿ‘‰ https://www.bmj.com/content/372/bmj.n214

Permanent link to this article: https://inheritedcancer.net/post50321/

ICARE Social Media Post April 2021

Reducing Hereditary Cancer Act

The ๐™๐™š๐™™๐™ช๐™˜๐™ž๐™ฃ๐™œ ๐™ƒ๐™š๐™ง๐™š๐™™๐™ž๐™ฉ๐™–๐™ง๐™ฎ ๐˜พ๐™–๐™ฃ๐™˜๐™š๐™ง ๐˜ผ๐™˜๐™ฉ is being proposed to ensure Medicare beneficiaries have access to inherited cancer genetic testing, increased screening, and risk-reducing procedures, when medically necessary & appropriate. Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Genetic testing is only …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post43021/

ICARE Social Media Post April 2021

Effect of Salpingo-Oophorectomy on Breast Cancer Risk in Women With BRCA1 or BRCA2 Pathogenic Variants

For more information, view the JAMA Oncology article available at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2776761

Permanent link to this article: https://inheritedcancer.net/post42821/

ICARE Social Media Post April 2021

Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment

For more information, read the recently published ASCO Daily News editorial led by ๐——๐—ฟ. ๐—ฆ๐—ผ๐—ป๐˜†๐—ฎ ๐—ฅ๐—ฒ๐—ถ๐—ฑ from Vanderbilt University Medical Center, which focused on racial disparities in breast cancer clinical trial enrollment: https://dailynews.ascopubs.org/do/10.1200/ADN.21.200499/full/

Permanent link to this article: https://inheritedcancer.net/post42321/

ICARE Social Media Post April 2021

Komen Disparities Resource

Check out Susan G. Komen’s “๐—ž๐—ป๐—ผ๐˜„ ๐—ฌ๐—ผ๐˜‚๐—ฟ ๐—›๐—ถ๐˜€๐˜๐—ผ๐—ฟ๐˜†, ๐—ž๐—ป๐—ผ๐˜„ ๐—ฌ๐—ผ๐˜‚๐—ฟ ๐—ฅ๐—ถ๐˜€๐—ธ” resource, which outlines disparities in breast cancer, how to understand your risk, and recommended screening and management practices. To learn more, please visit: ๐Ÿ‘‰ https://www.komen.org/about-komen/our-impact/breast-cancer/health-equities-initiative/know-your-history/ ๐Ÿ‘‰ https://blog.komen.org/news/black-history-month/

Permanent link to this article: https://inheritedcancer.net/post42021/

ICARE Social Media Post April 2021

Olaparib for Metastatic Breast Cancer

For more information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151

Permanent link to this article: https://inheritedcancer.net/post41321/

ICARE Social Media Post April 2021

Winter 2021 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Rebecca Smith explains how a genetic change (or mutation) is classified as pathogenic or benign. Check out Dr. Smith’s full response in our Winter 2021 newsletter at: https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/post40921/

ICARE Social Media Post April 2021

Fruits and Vegetables Lower Mortality

For further information, view the article available at:https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.048996

Permanent link to this article: https://inheritedcancer.net/post40621/

ICARE Social Media Post April 2021

Family Communication of Genetic Test Results Among Women with Inherited Breast Cancer Genes

Check out a recent article led by the ICARE team, published in the Journal of Genetic Counseling, outlining family communication of genetic test results among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Check out the full article at: https://onlinelibrary.wiley.com/doi/full/10.1002/jgc4.1356

Permanent link to this article: https://inheritedcancer.net/post40221/

ICARE Social Media Post March 2021

STK11: Cancer Risks and Risk Management

Gene: STK11 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Women:Breast cancer risk: Elevated at 40-60% – Recommend annual mammogram and breast MRI starting at around age 30. Ovarian tumor risk (typically benign sex cord/Sertoli cell tumors): Elevated at 18-21% – Recommend annual pelvic exam starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post33021/

ICARE Social Media Post March 2021

MUTYH: Cancer Risks and Risk Management

Gene: MUTYH Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Men & women with two mutations in MUTYH:Colon cancer risk: High risk – Recommend colonoscopy every 1-2 years beginning at age 25-30; colectomy considered based on polyp burden and age. Duodenal cancer risk: Elevated – Consider baseline …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32321/

ICARE Social Media Post March 2021

Winter 2021 Community Spotlight

In every ICARE newsletter we feature a ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐˜† ๐˜€๐—ฝ๐—ผ๐˜๐—น๐—ถ๐—ด๐—ต๐˜ to share their experience with inherited cancer. In the latest edition, Dave Dubin, co-founder of AliveAndKickn, shares his experience with Lynch Syndrome. Check out his full story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post31921/

ICARE Social Media Post March 2021

APC: Cancer Risks and Risk Management

๐—š๐—ฒ๐—ป๐—ฒ: ๐—”๐—ฃ๐—– Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 ๐— ๐—ฒ๐—ป & ๐—ช๐—ผ๐—บ๐—ฒ๐—ป:๐˜ˆ๐˜—๐˜Š mutation leading to classic form of Familial Adenomatous Polyposis (FAP):Colorectal cancer risk: >99% if untreated – Treatment is based on polyp burden and includes proctocolectomy (with subsequent endoscopic screening of the ileal pouch) or …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31621/

ICARE Social Media Post March 2021

Colorectal Cancer Risk Assessment Tool

In honor of ๐—–๐—ผ๐—น๐—ผ๐—ฟ๐—ฒ๐—ฐ๐˜๐—ฎ๐—น ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฒ๐˜€๐˜€ ๐— ๐—ผ๐—ป๐˜๐—ต, we wanted to highlight the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (CCRAT) designed for healthcare providers to use with select patients to estimate the risk of colorectal cancer. You may access the tool at https://ccrisktool.cancer.gov

Permanent link to this article: https://inheritedcancer.net/post31221/

ICARE Social Media Post March 2021

Three Articles: Breast Cancer Risks

For additional information about the: ใ€‹US-based study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa2005936 ใ€‹International study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa1913948 ใ€‹Accompanying editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2035083

Permanent link to this article: https://inheritedcancer.net/post30921/

ICARE Social Media Post March 2021

Breastfeeding and the Risk of Epithelial Ovarian Cancer Among Women with A BRCA1 or BRCA2 Mutation

For further information, view the article available at: https://www.gynecologiconcology-online.net/action/showPdf?pii=S0090-8258%2820%2933947-0

Permanent link to this article: https://inheritedcancer.net/post30221/

ICARE Social Media Post February 2021

Olaparib and Invasive Disease-Free Survival in Patients with BRCA, High-Risk, Early Breast Cancer

For additional information visit: https://www.onclive.com/view/adjuvant-olaparib-showcases-idfs-improvement-in-brca-high-risk-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post22321/

ICARE Newsletter Winter 2021

Inherited Breast Cancer Genes: Two New Important Articles Just Released

Results of a United States (U.S.)-based study1 and an international study2 were released in January in the New England Journal of Medicine and provide a much clearer picture about the role of inherited breast cancer genes in women without a family history of cancer, and how common these genes may be in the general population. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2021/

ICARE Newsletter Winter 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Released September 8th, 2020: Genetic testing criteria by cancer type: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Having multiple breast cancer diagnoses no longer depends on whether the diagnoses were on two different breasts Prostate Cancer: Now includes cribriform histology and ANY risk group (not just high-grade …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2021/

ICARE Newsletter Winter 2021

Exploring Disparities Among Those with Inherited Cancers

It has never been more urgent to ensure that advances in genomic technologies do not further widen existing cancer health disparities. In the fall of 2020, the American Association for Cancer Research (AACR) put forth a report focused on cancer health disparities, in which they highlighted several issues.1 Notably, disparities in inherited cancer care were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2021/

ICARE Newsletter Winter 2021

Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy

A study of 159 women, including BRCA1/2 carriers, who had a bilateral mastectomy with reconstruction and underwent breast MRI screening, showed few women had detection of breast cancer through MRI after their bilateral mastectomy. These results support the recommendation that BRCA1/2 carriers with or without breast cancer who have a bilateral mastectomy with reconstruction do …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2021/

ICARE Newsletter Winter 2021

Community Spotlight

My genes donโ€™t define me. I am AliveAndKickn. Pretty bold statement. AliveAndKickn is more than just a name. Itโ€™s a way of life. I joke that Lynch Syndrome is the genetic predisposition to colon cancer, endometrial cancer, other cancersโ€ฆand soccer. But thatโ€™s just me. Besides half a dozen surgeries since 1997, I have and still play and coach the game I love. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2021/

ICARE Newsletter Winter 2021

Learning You Have a Mutation in an Inherited Cancer Gene: Whatโ€™s Next?

The benefits achieved through genetic testing for inherited cancer only happen by acting upon the results. This can be through guiding cancer treatment, receiving appropriate cancer risk management strategies, and sharing results with at-risk family members so they too can benefit from this information. We recently reported on results of our study, made possible through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2021/

ICARE Newsletter Winter 2021

CHEK2 is NOT a Li-Fraumeni Syndrome Gene

An old study back in 1999 suggested that CHEK2 may be a Li-Fraumeni Syndrome gene.1 However, a subsequent report in 2002 clearly refuted this original assertion, and based on additional data and analysis concluded that โ€œโ€ฆ it is very unlikely that CHEK2 is an alternative Li-Fraumeni Syndrome susceptibility gene.โ€2 Another subsequent report in 2008 based …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2021/

ICARE Newsletter Winter 2021

Assessing How Pregnancy and Breastfeeding May Affect Cancer Risks in BRCA Carriers

Results of a recently published study suggested that pregnancy after breast cancer in BRCA carriers does not lead to a worse outcome in women or their fetuses.1 This information is reassuring for BRCA carriers who have had a prior diagnosis of breast cancer and are considering having children. In another study among female BRCA carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2021/

ICARE Newsletter Winter 2021

Ask the Expert

In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Rebecca Smith, PhD, Laboratory Director at Genetics Associates, Inc. with over 20 years of experience in biomedical research and 7 years of experience in clinical laboratory diagnostics. If you have a question …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nlw2021/

ICARE Newsletter Winter 2021

Inherited Cancer Treatment: Updates and Relevant Policies

Over the last several months, the American Society of Clinical Oncology published a number of guidelines related to the use of PARP inhibitors among those with BRCA-associated cancers, including guidelines focused on ovarian cancer,1 metastatic pancreatic cancer,2 and breast cancer.3 Additionally, costs of drugs also have great potential to influence policy, highlighting the importance of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2021/

ICARE Social Media Post February 2021

ICARE Winter 2021 Newsletter

The ICARE Winter 2021 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with a genomics expert, and an inspiring community spotlight piece. You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2021-Winter-Newsletter.pdf. Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post20921/

ICARE Social Media Post February 2021

Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers

Our team recently published “Sharing Genetic Test Results with Family Members of ๐˜‰๐˜™๐˜Š๐˜ˆ, ๐˜—๐˜ˆ๐˜“๐˜‰2, ๐˜Š๐˜๐˜Œ๐˜’2, and ๐˜ˆ๐˜›๐˜” Carriers” in ๐˜—๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต ๐˜Œ๐˜ฅ๐˜ถ๐˜ค๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜ข๐˜ฏ๐˜ฅ ๐˜Š๐˜ฐ๐˜ถ๐˜ฏ๐˜ด๐˜ฆ๐˜ญ๐˜ช๐˜ฏ๐˜จ Special Issue on Genetics. View the article available at:https://www.sciencedirect.com/science/article/pii/S0738399120306832 Challenges and barriers to family sharing included concern for family members’ reactions, complexities of information, lack of closeness, perceived relevance, & emotional impact. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post20821/

ICARE Social Media Post February 2021

Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers

Check out a recent review article led by the ICARE team, published in ๐˜Œ๐˜น๐˜ฑ๐˜ฆ๐˜ณ๐˜ต ๐˜™๐˜ฆ๐˜ท๐˜ช๐˜ฆ๐˜ธ ๐˜ฐ๐˜ง ๐˜”๐˜ฐ๐˜ญ๐˜ฆ๐˜ค๐˜ถ๐˜ญ๐˜ข๐˜ณ ๐˜‹๐˜ช๐˜ข๐˜จ๐˜ฏ๐˜ฐ๐˜ด๐˜ต๐˜ช๐˜ค๐˜ด, outlining strategies to improve the identification of inherited breast cancer gene carriers. Check out the full article at: https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1816829?needAccess=true

Permanent link to this article: https://inheritedcancer.net/post20221/

ICARE Social Media Post January 2021

Male Breast Cancer Global Alliance

The Male Breast Cancer Global Alliance shares stories from male breast cancer survivors all over the world. To learn more and find resources for affected men and their families, please visit www.mbcglobalalliance.org. The Male Breast Cancer Global Alliance also developed printable and shareable cards in over 20 languages outlining the proper way to do self-breast …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12621/

ICARE Social Media Post January 2021

COVID-19 Vaccine Myths

ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  ย  Although we don’t typically post on vaccines, given the public health importance of the COVID-19 vaccine and the questions we have received related to whether the vaccine could change one’s DNA, we …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12221/

ICARE Social Media Post January 2021

Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM

Check out a new article by the ICARE team, published in Patient Education and Counseling, evaluating the motivators and barriers to sharing personal genetic test results with family members. The article is ๐—ณ๐—ฟ๐—ฒ๐—ฒ to access and download ๐˜‚๐—ป๐˜๐—ถ๐—น ๐— ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐Ÿฑ๐˜๐—ต at: https://www.sciencedirect.com/science/article/pii/S0738399120306832

Permanent link to this article: https://inheritedcancer.net/post11521/

ICARE Social Media Post January 2021

Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition

Check out a study led by the ICARE team, published with @SpringerNature in the Journal of Cancer Education, outlining the evaluation and refinement strategies of an interactive web-based tool developed to provide education about inherited cancer risk. Check out a full-text view-only version of the paper at https://rdcu.be/cc8sR or read the abstract at https://pubmed.ncbi.nlm.nih.gov/33400205/ (PMID: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11221/

ICARE Social Media Post January 2021

Family Sharing Resources: GeneSHARE

With the tremendous advances in gene-based care among those at risk for inherited cancer, we are trying to develop and improve tools and strategies to make it easier for more people to benefit from genetic testing. We are excited to share with you a free online toolkit called ๐—š๐—ฒ๐—ป๐—ฒ๐—ฆ๐—›๐—”๐—ฅ๐—˜, which is aimed at helping patients …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10821/

ICARE Social Media Post January 2021

National Cancer Institute (NCI) Cancer Genetics PDQ

For further information, check out the National Cancer Institute’s PDQยฎ Cancer Genetics Summary available at: https://www.cancer.gov/publications/pdq/information-summaries/genetics

Permanent link to this article: https://inheritedcancer.net/post10521/

ICARE Social Media Post December 2020

Genetic Testing in Women with Breast Cancer

Approximately 4,000 women with breast cancer were tested for mutations in nine breast cancer genes – 6.2% had mutations in at least one of the nine genes, and 2.7% had mutations in either ๐˜ฝ๐™๐˜พ๐˜ผ1 or ๐˜ฝ๐™๐˜พ๐˜ผ2. Comparisons between women who did versus did not meet National Comprehensive Cancer Network (NCCN) guidelines for testing showed that: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122920/

ICARE Social Media Post December 2020

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

For further information, read the article available at: https://jnccn.org/…/journals/jnccn/18/11/article-p1528.xml

Permanent link to this article: https://inheritedcancer.net/post122220/

ICARE Social Media Post December 2020

CHEK2 is NOT a Li-Fraumeni Syndrome Gene

For additional details, read the articles at the links below: ๐Ÿญ๐Ÿต๐Ÿต๐Ÿต: https://pubmed.ncbi.nlm.nih.gov/10617473/ ๐Ÿฎ๐Ÿฌ๐Ÿฌ๐Ÿฎ: https://pubmed.ncbi.nlm.nih.gov/12442270/ ๐Ÿฎ๐Ÿฌ๐Ÿฌ๐Ÿด: https://pubmed.ncbi.nlm.nih.gov/18178638/

Permanent link to this article: https://inheritedcancer.net/post121820/

ICARE Social Media Post December 2020

CDH1 Cancer Risks

When a ๐˜พ๐˜ฟ๐™ƒ1 mutation is identified, several factors should be considered to figure out what the cancer risks might be and what medical management should be advised. Specifically, differences in cancer risks among those with a ๐˜พ๐˜ฟ๐™ƒ1 mutation are not well understood.   Identifying a ๐˜พ๐˜ฟ๐™ƒ1 mutation in families with hereditary diffuse gastric cancer (HDGC) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121520/

ICARE Social Media Post December 2020

PALB2-associated Metastatic Breast Cancer

For further information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151

Permanent link to this article: https://inheritedcancer.net/post121120/

ICARE Social Media Post December 2020

New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines

The National Comprehensive Cancer Network (NCCN) released new guidelines on November 20th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/…/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post120820/

ICARE Social Media Post December 2020

Broader Germline Testing for Urothelial Cancer

The most common inherited form of urothelial cancers is Lynch Syndrome. However, a study showed that of 586 individuals with urothelial cancer, 80 had a mutation in an inherited cancer gene (14%). Mutations in several genes were observed; however, ๐™ˆ๐™Ž๐™ƒ2 and ๐˜ฝ๐™๐˜พ๐˜ผ2 were both significantly associated with urothelial cancer (odds ratio of 3.7).   Confirmatory …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120420/

ICARE Social Media Post December 2020

Breast Cancer Polygenic Risk Score May Help Predict Risk of Contralateral Disease

For further information, view the article available at: https://www.sciencedirect.com/…/pii/S0002929720303219

Permanent link to this article: https://inheritedcancer.net/post120120/

ICARE Social Media Post November 2020

Olaparib May Be Cost-Effective Maintenance Treatment For Women With Newly Diagnosed Ovarian Cancer and BRCA Mutation

For further information, view the article available at: https://www.gynecologiconcology-online.net/…/fulltext

Permanent link to this article: https://inheritedcancer.net/post112720/

ICARE Social Media Post November 2020

Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations

Check out the original article by visiting: https://pubmed.ncbi.nlm.nih.gov/32673153/

Permanent link to this article: https://inheritedcancer.net/post112420/

ICARE Social Media Post November 2020

ASCO Guideline Updates: Breast Cancer

The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers:   ๐˜ฝ๐™๐˜พ๐˜ผ1/2 โ€ข Consider breast-conserving therapy โ€ข Consider nipple-sparing mastectomy, if medically appropriate โ€ข Advanced breast cancer: โซธ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy โซธ Platinum agents are recommended …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post112020/

ICARE Social Media Post November 2020

ASCO Guidelines for Patients with Metastatic Pancreatic Cancer

For additional details, refer to the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01364

Permanent link to this article: https://inheritedcancer.net/post111720/

ICARE Social Media Post November 2020

Polygenic Risk Scores in Predicting Breast Cancer Risk

For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/PO.19.00360

Permanent link to this article: https://inheritedcancer.net/post111320/

ICARE Social Media Post November 2020

B-GREAT 2020 Newsletter

The B-GREAT 2020 Newsletter is now available! Check out this latest edition for research updates and information about racial inequalities in healthcare. You can read the newsletter by visiting: https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-Newsletter-2020.pdf. Please feel free to share with family members, friends, and/or your healthcare providers.  We will be publishing these newsletters twice a year starting in 2021. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111020/

ICARE Social Media Post November 2020

Clinical Trial Participation Powers Patient’s Positive Attitude

Brooke Thomas has leaned on 12 years of experience as a medical social worker and found ways to stay positive and upbeat through it all – and she has a lot to be positive about these days, thanks to an amazing response to her treatment as part of a clinical trial at Vanderbilt-Ingram Cancer Center. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110620/

ICARE Social Media Post November 2020

Identifying Individuals At-Risk for Inherited Cancer: Disparities Among Ovarian Cancer Patients

This study highlights disparities among ovarian cancer patients. For further information, view the article at: https://pubmed.ncbi.nlm.nih.gov/30964716/

Permanent link to this article: https://inheritedcancer.net/post110320/

ICARE Social Media Post October 2020

CDH1: Cancer Risks and Risk Management

Gene: ๐˜พ๐˜ฟ๐™ƒ๐Ÿญ Cancer Risks and Management per NCCN Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021 and Gastric Version 3.2020: ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Breast cancer risk: Elevated at 55% – Recommend annual mammogram starting at age 30; consider breast MRI with contrast starting at age 30. ๐— ๐—ฒ๐—ป ๐—ฎ๐—ป๐—ฑ ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Stomach cancer risk: Elevated at 83% for women, and 67% …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post103020/

ICARE Social Media Post October 2020

Polygenic Risk Scores in Refining Breast Cancer Risks

For further information, view the article available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767768

Permanent link to this article: https://inheritedcancer.net/post102720/

ICARE Social Media Post October 2020

PTEN: Cancer Risks and Risk Management

Gene: ๐™‹๐™๐™€๐™‰ Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Breast cancer risk: Elevated at 85% – Recommend annual mammogram starting at age 30-35 (or 5-10 years before the earliest known breast cancer in the family); consider breast MRI with contrast starting at age 30-35; consider …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102320/

ICARE Social Media Post October 2020

Three Genetic Variants Identified That May Raise Breast Cancer Risks in Men

For more information, view the article available at: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaa101/5885091

Permanent link to this article: https://inheritedcancer.net/post102020/

ICARE Social Media Post October 2020

TP53: Cancer Risks and Risk Management

Gene: ๐™๐™‹๐Ÿฑ๐Ÿฏ Syndrome: Li-Fraumeni Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Breast cancer risk: Elevated at 54% – Recommend clinical breast exam every 6-12 months starting at age 20, annual breast MRI with contrast starting at age 20, and annual mammogram starting at age 30; …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101620/

ICARE Social Media Post October 2020

New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer

New guidelines for the use of PARP inhibitors to treat ovarian cancer among those with BRCA1 or BRCA2 mutations were published through the American Society of Clinical Oncology (ASCO) to guide providers about the role of this class of drugs in the management of this type of cancer. Link to the guidelines are available at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101320/

ICARE Social Media Post October 2020

CHEK2: Cancer Risks and Risk Management

Gene: ๐˜พ๐™ƒ๐™€๐™†2 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 & Breast/Ovarian/Pancreatic Version 1.2021: ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Breast Cancer Risk: Elevated at 28-44% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs with contrast starting at age 40. ๐— ๐—ฒ๐—ป ๐—ฎ๐—ป๐—ฑ ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Colorectal Cancer Risk: Elevated …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100920/

ICARE Social Media Post October 2020

Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer

Among BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that did not progress), compared to those treated with ONLY chemotherapy. To read the full article visit: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30447-2/fulltext [This finding was previously outlined last year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100620/

ICARE Social Media Post October 2020

ATM: Cancer Risks and Risk Management

Gene: ๐˜ผ๐™๐™ˆ Cancer Risks and Management (per NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021) ๐—ช๐—ผ๐—บ๐—ฒ๐—ป: Breast cancer risk: Elevated at 30% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs starting at age 40. Ovarian cancer risk: Possibly increased, not well established – Manage based on family history. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100220/

ICARE Social Media Post September 2020

Living with Lynch 2020 Virtual Patient Workshop

SJoin the Colon Cancer Coalition and AliveAndKickn for the Living with Lynch 2020 Virtual Patient Workshop on๐—™๐—ฟ๐—ถ๐—ฑ๐—ฎ๐˜†, ๐—ข๐—ฐ๐˜๐—ผ๐—ฏ๐—ฒ๐—ฟ ๐Ÿต๐˜๐—ต ๐—ณ๐—ฟ๐—ผ๐—บ ๐Ÿญ๐—ฝ๐—บ-๐Ÿฑ๐—ฝ๐—บ ๐—˜๐—ง to hear unique patient perspectives and the latest information from experts on Lynch syndrome.  Visit https://www.livingwithlynch.org/2020-living-with-lynch to register for this free workshop today! 

Permanent link to this article: https://inheritedcancer.net/post92920/

ICARE Social Media Post September 2020

AACR Cancer Disparities Progress Report 2020

The American Association for Cancer Research (AACR) published a Cancer Disparities Progress Report. “… our limited knowledge of cancer biology in racial and ethnic minorities, including their inherited cancer predisposition and the genomic underpinnings of cancer initiation and progression, diminishes the potential of precision medicine in these populations.” This report discusses relevant information about inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post92520/

ICARE Social Media Post September 2020

FDA Grants Breakthrough Therapy Status to MK-6482 for Treatment of Patients With VHL Disease-Associated Renal Cell Carcinoma

For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc   Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract

Permanent link to this article: https://inheritedcancer.net/post92220/

ICARE Social Media Post September 2020

Rucaparib May Have Antitumor Activity in Male BRCA Carriers with Metastatic Prostate Cancer

For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01035

Permanent link to this article: https://inheritedcancer.net/post91820/

ICARE Social Media Post September 2020

ICARE Summer 2020 Newsletter

The ICARE Summer 2020 Newsletter is now available! Check out this latest edition for recent research and clinical updates as well as a Q&A with a nationally renowned clinical geneticist from Vanderbilt-Ingram Cancer Center.    You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2020-Summer-Newsletter.pdf    Please feel free to share with family members, friends, and/or your …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91620/

ICARE Social Media Post September 2020

NCCN Genetic Testing Criteria Updates by Cancer

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing criteria by cancer type as follows:   Breast Cancer:  Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Now having multiple breast cancer diagnoses is NOT dependent on whether the diagnoses were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91520/

ICARE Social Media Post September 2020

NCCN Breast Cancer Pathology Updates

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91420/

ICARE Social Media Post September 2020

NCCN Genetic Testing Choice Updates

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing choices and considerations as follows: Choice of multi-gene panel may be guided by genes included, analyses offered, and financial assistance programs available for family testing Significant limitations in interpretations of polygenic risk scores:  NOT recommended for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91120/

ICARE Social Media Post September 2020

NCCN Breast Cancer Risk Management Updates by Gene

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to breast cancer risk management recommendations by gene as follows:  NBN – high-risk breast screening was removed as there is insufficient evidence to support high cancer risks BARD1 – added consideration for high-risk breast screening starting at age 40  …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91020/

ICARE Social Media Post September 2020

ACMG Guidelines for Genetic Testing for All Breast Cancer

Check out Vanderbilt’s article about genetic testing considerations at: https://discover.vumc.org/2020/02/genetic-testing-considerations-for-breast-cancer-patients/     Check out the original document from the American College of Medical Genetics and Genomics at: https://www.nature.com/articles/s41436-019-0712-x

Permanent link to this article: https://inheritedcancer.net/post90820/

ICARE Social Media Post September 2020

GREM1 Duplication

The GREM1 gene leads to hereditary mixed polyposis syndrome, characterized by multiple polyps of mixed pathology and high risks for colorectal cancer.   A specific duplication in the 5′ regulatory region of the GREM1 gene has been found in a subset of Ashkenazi Jewish individuals with hereditary mixed polyposis syndrome; therefore, GREM1 genetic testing is …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90420/

ICARE Social Media Post September 2020

Biallelic Mutations in BRCA1 Cause Fanconi Anemia

BRCA1 is not typically thought to be one of the genes which cause Fanconi anemia. However, rare cases of individuals with biallelic BRCA1 mutations (mutations in both copies of the gene) have been reported. One case involved a woman who had breast cancer at age 23, and was born with multiple birth defects consistent with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90120/

ICARE Social Media Post August 2020

Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers

Among 4,500 post-menopausal women with breast cancer, 3.55% had a mutation in a gene associated with inherited breast cancer (3-fold higher than what was seen among women who were cancer-free). BRCA1/2 mutations were seen more frequently in women diagnosed with breast cancer at or below age 65 (2.21%) compared to those diagnosed after age 65 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82820/

ICARE Social Media Post August 2020

Pheochromocytoma and Paraganglioma Genetic Testing

More than 40% of patients with pheochromocytoma or paraganglioma, regardless of age and family history, carry an inherited gene mutation. Given that gene mutation carriers may benefit from gene-specific cancer screening, all individuals diagnosed with one of these tumors should seek genetic counseling to discuss genetic testing options. Genes that predispose to pheochromocytoma and paraganglioma …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82520/

ICARE Social Media Post August 2020

Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers

Individuals with a CDH1 mutation and classic personal and family history of diffuse gastric (stomach) cancer have a very high risk of developing and dying from stomach cancer, if they do not have preventive surgery to remove their stomach. A simulation study to assess prophylactic total gastrectomy (PTG; the removal of the stomach to prevent …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82120/

ICARE Social Media Post August 2020

MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction

A study of 159 women, including BRCA carriers, who had bilateral mastectomy with reconstruction, underwent breast MRI screening. The results showed few women had detection of breast cancer through MRI, after their bilateral mastectomy. These results support the recommendation against screening MRI in women who have had bilateral mastectomy with reconstruction due to a diagnosis …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81820/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Neurofibromatosis Type 1

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Neurofibromatosis Type 1 (NF1):  The FDA granted selumetinib (a MEK inhibitor) breakthrough therapy designation for treatment of inoperable plexiform neurofibromas.

Permanent link to this article: https://inheritedcancer.net/8nls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Lynch Syndrome

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Lynch Syndrome:  Colorectal Cancer: Among patients with MSI-H or MMR-deficient colorectal cancers (frequently seen among those with Lynch syndrome), pembrolizumab …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2020/

ICARE Newsletter Summer 2020

Ask the Expert

In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Georgia Wiesner, MD, MS, a nationally renowned clinical cancer geneticist, who is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine, and the Director of the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2020/

ICARE Newsletter Summer 2020

Identifying Individuals At-Risk for Inherited Cancer

We have known for a while that many people who have mutations in BRCA1/2 and other inherited cancer risk genes are unaware of their mutation as they have not yet had genetic testing. A recent study among women aged 20 or older living in California and Georgia, which included almost 80,000 breast cancer patients and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2020/

ICARE Newsletter Summer 2020

Community Spotlight

PTEN is one of the bodyโ€™s tumor suppressor genes, which controls cell growth. When a PTEN mutation is present, cells may grow uncontrollably, causing tumors to develop that may become cancerous. A patient born with a PTEN mutation is at high risk for developing breast, thyroid, kidney, colon, and endometrial cancer. My PTEN journey began …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Von-Hippel Lindau (VHL) Disease

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Von-Hippel Lindau (VHL) Disease:  Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among BRCA1/2 Carriers

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: BRCA1/2 Carriers:  Breast Cancer: For those with later stage or metastatic breast cancer, the FDA currently has approvals for the use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2020/

ICARE Newsletter Summer 2020

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines (Version 1.2020, posted July 21, 2020) For individuals with Lynch Syndrome: Cancer risks were updated based on information from recent studies: Main updates included cancer risks in PMS2 (endometrial, ovarian, and prostate cancer), MSH2 and EPCAM (prostate and brain cancer), and MSH6 (prostate …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2020/

ICARE Newsletter Summer 2020

Guideline-Concordant Care Among Women with Inherited Cancer Gene Mutations

Testing for inherited cancer among breast cancer patients has tremendous potential to guide appropriate care following testing. Yet, a number of efforts suggest that women are not consistently receiving care according to current national guidelines based on their genetic test result. In fact, results from studies suggest many women for whom risk-reducing mastectomy would not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2020/

ICARE Newsletter Summer 2020

Polygenic Risk Scores and Colon Cancer

A recent study focused on how polygenic risk scores (PRS) may be related to colorectal cancers. Of note, PRS are calculated using genetic differences throughout someoneโ€™s DNA, in combination with their clinical and family history of cancer. PRS, alongside environmental and lifestyle risk factors, may help to identify people who may benefit from screening at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2020/

ICARE Social Media Post August 2020

Inherited Prostate Cancer Risk

Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81420/

ICARE Social Media Post August 2020

CDC Resource for Free Breast Cancer Screening

We are here to help! Our followers asked us to provide information about screening resources for women with hereditary breast cancer. We would like to make folks aware about a CDC program that provides free breast cancer screening for women who are uninsured and underinsured. โฃโฃ โฃโฃ Check out more information at: https://www.cdc.gov/cancer/nbccedp/ โฃโฃ

Permanent link to this article: https://inheritedcancer.net/post81120/

ICARE Social Media Post August 2020

Presymptomatic BRCA1/2 Carriers May Have Better Outcomes

Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2768011

Permanent link to this article: https://inheritedcancer.net/post80720/

ICARE Social Media Post August 2020

Disparities in BRCA Counseling Across Diverse Populations

A recently published study based on data from our participants showed that few young Black women with breast cancer see a genetic counselor AND those with insurance are LESS likely to see a genetic counselor. โฃโฃ โฃโฃ For more information, check out the full study at: https://www.nature.com/articles/s41436-020-0762-0 

Permanent link to this article: https://inheritedcancer.net/post80420/

ICARE Social Media Post August 2020

Genes That Predispose African American Women to Breast Cancer

A recently published study based on data including our participants identified genes that predispose African American patients to breast cancer.  For more information, check out the full study at: https://academic.oup.com/jnci/article/doi/10.1093/jnci/djaa040/5838706.

Permanent link to this article: https://inheritedcancer.net/post80320/

ICARE Social Media Post July 2020

Cancer Risks in Men with BRCA1 and BRCA2 Pathogenic Variants

Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2767423

Permanent link to this article: https://inheritedcancer.net/post73120/

ICARE Social Media Post July 2020

Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines

The National Comprehensive Cancer Network (NCCN) released new guidelines for 2020 on July 21, 2020. The big changes included refining some of the risks for genes involved in Lynch Syndrome, and providing specific guidance about cancer screening that may slightly differ by gene. You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72420/

ICARE Social Media Post July 2020

Racial Inequalities in Genetics

[ngg src=”galleries” ids=”1″ display=”basic_slideshow” arrows=”1″ show_thumbnail_link=”0″]It is important to talk about racial inequalities in healthcare as it affects the care received among Black patients. Through our research efforts, we not only want to address the issue of racism but also think about ways to make healthcare more equitable. A recently published study including our research …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72120/

ICARE Social Media Post July 2020

Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation

A study comparing women with two CHEK2 mutations to one CHEK2 mutation showed that those with two mutations were: -more likely to get breast cancer (80.6% versus 41.2%) -more likely to be diagnosed at or below age 50 (61.3% versus 23.9%) -more likely to have a second breast cancer diagnosis (22.6% versus 8.1%) These findings …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71720/

ICARE Social Media Post July 2020

Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer

Individuals with a first-degree relative (for example, parent, sibling, or child) with blood cancer, such as lymphoma, have a higher chance of being diagnosed with blood-related cancer (i.e., hematologic malignancy), according to a recent study. The risk to develop certain blood cancers depends on how closely related the relative is (e.g., higher risks for first-degree …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71420/

ICARE Social Media Post July 2020

BRCA1/2 and Other Gene Carriers with Breast Cancer Donโ€™t Always Receive Recommended Treatment

BRCA1/2 and other gene mutation carriers with early stage breast cancer are not always receiving cancer treatment as recommended by national guidelines. Even though more and more people have been tested for hereditary cancer over the years, using this information accurately to guide treatment has not been as successful. These findings highlight the need for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71020/

ICARE Social Media Post July 2020

Pancreatic Cancer Can Run in Families

Individuals with a family history of pancreatic cancer have a higher risk to develop pancreatic cancer. A recent study reported the following pancreatic cancer risks compared to the general population, based on relationship to an individual with pancreatic cancer: First-degree relative (e.g., parent, sibling, child) โ€“ 1.76 fold higher Second-degree relative (e.g., aunts, uncles, grandparents) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70720/

ICARE Social Media Post July 2020

Community Spotlight: Mari-Lynn Slayton

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2016 ICARE Newsletter is Mari-Lynn Slayton, who was found to have a PALB2 mutation after two breast cancer diagnoses. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post70220/

ICARE Social Media Post June 2020

Advances in Treatment for Colorectal Cancer

On June 29, 2020, the FDA approved the use of Keytruda (pembrolizumab), as first-line treatment in unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Among people with Lynch syndrome, the risk for colorectal cancer (which often has microsatellite instability and/or mismatch-repair deficiency) is raised. Keytruda (pembrolizumab) showed to double the progression-free …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post63020/

ICARE Social Media Post June 2020

Higher Chance of VUS Results in Minorities

Asian, Hispanic, and Black women with breast cancer had higher rates of variants of uncertain significance (VUS) on genetic test results for hereditary cancer genes compared to White women with breast cancer according to a recent study. Check out the full article at https://link.springer.com/article/10.1007%2Fs13187-019-01646-8

Permanent link to this article: https://inheritedcancer.net/post62620/

ICARE Social Media Post June 2020

Community Spotlight: Kelly Frank

June is cancer survivor month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2019 ICARE Newsletter is Kelly Frank, who was found to have a BRIP1 mutation after an ovarian cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post62320/

ICARE Social Media Post June 2020

Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer

In a study of 914 women with different breast cancer subtypes, overall pathologic complete response rates were: Higher in those with BRCA1/2 mutations (60.4% versus 46.7%) No differences were seen in those with mutations in other inherited cancer genes Among patients with triple-negative breast cancer, BRCA1/2 mutations had highest response rates to treatment in both …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61920/

ICARE Social Media Post June 2020

Community Spotlight: Patricia Blumenthal

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Summer 2018 ICARE Newsletter is Patricia Blumenthal, who was found to have a BRCA2 mutation. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post61620/

ICARE Social Media Post June 2020

Advances in BRCA1/2 Breast Cancer Treatment

Through a randomized phase 2 study (called the INFORM trial) among BRCA1/2 carriers with breast cancer, cisplatin was no better in inducing pathologic complete remission compared to AC. The pathologic complete remission rate was 18% for cisplatin and 26% for AC. Cisplatin is not better than other chemotherapy for induction therapy for breast cancers in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61220/

ICARE Social Media Post June 2020

Community Spotlight: Christy Mattey

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Winter 2017 ICARE Newsletter is Christy Mattey, who was found to have a CHEK2 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post60920/

ICARE Social Media Post June 2020

Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine

In BRCA1/2 or PALB2 carriers with stage 3 or 4 pancreatic cancer, the combination of cisplatin + gemtricitabine with veliparib (a PARP inhibitor), did NOT seem to provide additional benefit over cisplatin + gemtricitabine alone. Through this phase 2 randomized control trial, response rates in both treatment arms were high with similar overall survival rates. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60520/

ICARE Social Media Post June 2020

Community Spotlight: Terry Arnold

June is Cancer Survivor Month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Summer 2017 ICARE Newsletter is Terry Arnold, who was found to have a BRCA1 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post60220/

ICARE Social Media Post May 2020

Platinum Based Chemotherapy for Metastatic Pancreatic Cancer

A recent study found that patients with metastatic pancreatic cancer who had mutations in the DNA repair genes (either inherited or just in the tumor) had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations. Check out the link to full article: https://clincancerres.aacrjournals.org/content/early/2020/05/20/1078-0432.CCR-20-0418

Permanent link to this article: https://inheritedcancer.net/post52920/

ICARE Social Media Post May 2020

Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE

A new article was recently published based on data from BRCA1/2, PALB2, CHEK2, and ATM carriers in ICARE. Findings suggest potential overtreatment through risk-reducing surgery among women with pathogenic/likely pathogenic variants in breast cancer genes. This highlights the importance of promoting guideline-adherent, risk-appropriate care. Check out the full article at https://rdcu.be/b4mbg

Permanent link to this article: https://inheritedcancer.net/post52620/

ICARE Social Media Post May 2020

Advances in Treatment for Metastatic Prostate Cancer: Olaparib

On May 19, 2020 the FDA approved the use of olaparib (Lynparza) as treatment in BRCA and other gene carriers (homologous recombination repair genes) with metastatic castration-resistant prostate cancer who have been treated with enzalutamide or abiraterone. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer

Permanent link to this article: https://inheritedcancer.net/post52220/

ICARE Social Media Post May 2020

Advances in Treatment for Metastatic Prostate Cancer: Rucaparib

On May 15, 2020 the FDA approved the use of rucaparib (Rubraca) as treatment in BRCA carriers with metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Link to full article: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate

Permanent link to this article: https://inheritedcancer.net/post51920/

ICARE Social Media Post May 2020

MRI May Detect Breast Cancer Earlier than Mammograms

The National Comprehensive Cancer Network (NCCN) currently recommends an annual breast MRI and an annual mammography for high-risk women (lifetime breast cancer risk at or above 20%). Among women at high risk for breast cancer, MRI detected breast cancer at an earlier stage than mammograms. Women with BRCA1/2 and TP53 were NOT included in this …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51520/

ICARE Social Media Post May 2020

Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab

On May 8, 2020 the FDA approved the use of olaparib (Lynparza) as first-line maintenance treatment in BRCA1/2 carriers (deleterious or suspected deleterious mutations) and/or a genomic instability, with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary

Permanent link to this article: https://inheritedcancer.net/post51220/

ICARE Social Media Post May 2020

Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib

In recognition of World Ovarian Cancer Day, we’d like to share some exciting results from a study of women with ovarian cancer and a BRCA mutation: In a recent phase III trial, olaparib (PARP inhibitor) showed improved response and progression-free survival compared with chemotherapy (without platinum) in BRCA carriers with platinum-sensitive relapsed ovarian cancer who …

Continue reading